



US010245450B2

(12) **United States Patent**
Slayton et al.

(10) **Patent No.:** **US 10,245,450 B2**
(45) **Date of Patent:** ***Apr. 2, 2019**

(54) **ULTRASOUND PROBE FOR FAT AND CELLULITE REDUCTION**

(71) Applicant: **Guided Therapy Systems, LLC**, Mesa, AZ (US)

(72) Inventors: **Michael H. Slayton**, Tempe, AZ (US);
Peter G. Barthe, Phoenix, AZ (US);
Inder Raj S. Makin, Mesa, AZ (US)

(73) Assignee: **Guided Therapy Systems, LLC**, Meza, AZ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/996,295**

(22) Filed: **Jun. 1, 2018**

(65) **Prior Publication Data**

US 2018/0272159 A1 Sep. 27, 2018

Related U.S. Application Data

(63) Continuation of application No. 15/821,281, filed on Nov. 22, 2017, now Pat. No. 10,010,725, which is a (Continued)

(51) **Int. Cl.**
A61N 7/02 (2006.01)
A61B 8/14 (2006.01)
(Continued)

(52) **U.S. Cl.**
CPC **A61N 7/02** (2013.01); **A61B 8/14** (2013.01); **A61B 8/429** (2013.01); **A61B 8/4483** (2013.01);
(Continued)

(58) **Field of Classification Search**
CPC A61N 7/02; A61N 7/00; A61N 2007/0008; A61B 8/14; A61B 8/429; A61B 8/4483;
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,427,348 A 9/1947 Bond et al.
2,792,829 A 2/1952 Calosi
(Continued)

FOREIGN PATENT DOCUMENTS

CN 104027893 9/2014
DE 4029175 3/1992
(Continued)

OTHER PUBLICATIONS

Ulthera, Inc., Petitioner Notice of Appeal to Federal Circuit 2018-1542 re: IPR2016-01459; 4 pages from [001] (no appendices) (Filed Feb. 9, 2018).

(Continued)


Primary Examiner — Bo Joseph Peng

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson & Bear LLP

(57) **ABSTRACT**

A method and system for providing ultrasound treatment to a tissue that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis. An embodiment delivers ultrasound energy to the region creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. An embodiment can also include ultrasound imaging configurations using the same or a separate probe before, after or during the treatment. In addition various therapeutic levels of ultrasound can be used to increase the speed at which fat metabolizes. Additionally the mechanical action of ultrasound physically breaks fat cell clusters and stretches the fibrous bonds. Mechanical action will also enhance lymphatic drainage, stimulating the evacuation of fat decay products.

20 Claims, 18 Drawing Sheets



Related U.S. Application Data

continuation of application No. 15/650,246, filed on Jul. 14, 2017, now Pat. No. 9,827,450, which is a continuation of application No. 15/374,918, filed on Dec. 9, 2016, now Pat. No. 9,707,412, which is a continuation of application No. 15/041,829, filed on Feb. 11, 2016, now Pat. No. 9,522,290, which is a continuation of application No. 14/550,720, filed on Nov. 21, 2014, now Pat. No. 9,283,410, which is a continuation of application No. 14/164,598, filed on Jan. 27, 2014, now Pat. No. 8,915,854, which is a continuation of application No. 13/789,562, filed on Mar. 7, 2013, now Pat. No. 8,636,665, which is a continuation of application No. 13/356,405, filed on Jan. 23, 2012, now Pat. No. 8,672,848, which is a continuation of application No. 11/163,154, filed on Oct. 6, 2005, now Pat. No. 8,331,180.

- (60) Provisional application No. 60/616,753, filed on Oct. 6, 2004.

(51) Int. Cl.

A61B 8/00 (2006.01)

A61B 8/08 (2006.01)

G01S 15/89 (2006.01)

A61N 7/00 (2006.01)

A61B 90/00 (2016.01)

(52) U.S. Cl.

CPC *A61B 8/461* (2013.01); *A61B 8/483* (2013.01); *A61N 7/00* (2013.01); *G01S 15/8906* (2013.01); *G01S 15/8936* (2013.01); *H05K 999/99* (2013.01); *A61B 8/4455* (2013.01); *A61B 2090/378* (2016.02); *A61N 2007/0008* (2013.01)

(58) Field of Classification Search

CPC ... *A61B 8/461*; *A61B 8/438*; *A61B 2090/378*; *A61B 8/4455*; *G01S 15/8906*; *G01S 15/8936*; *H05K 999/99*

See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|-------------|---------|----------------|-------------|---------|-------------------|
| 3,913,386 A | 10/1975 | Saglio | 4,513,749 A | 4/1985 | Kino |
| 3,965,455 A | 6/1976 | Hurwitz | 4,513,750 A | 4/1985 | Heyman et al. |
| 3,992,925 A | 11/1976 | Perilhou | 4,527,550 A | 7/1985 | Ruggera et al. |
| 4,039,312 A | 8/1977 | Patru | 4,528,979 A | 7/1985 | Marchenko |
| 4,059,098 A | 11/1977 | Murdock | 4,534,221 A | 8/1985 | Fife et al. |
| 4,101,795 A | 7/1978 | Fukumoto | 4,566,459 A | 1/1986 | Umemura et al. |
| 4,151,834 A | 5/1979 | Sato et al. | 4,567,895 A | 2/1986 | Putzke |
| 4,166,967 A | 9/1979 | Benes et al. | 4,586,512 A | 5/1986 | Do-Huu |
| 4,211,948 A | 7/1980 | Smith et al. | 4,601,296 A | 7/1986 | Yerushalmi |
| 4,211,949 A | 7/1980 | Briskin et al. | 4,620,546 A | 11/1986 | Aida et al. |
| 4,213,344 A | 7/1980 | Rose | 4,637,256 A | 1/1987 | Sugiyama et al. |
| 4,276,491 A | 6/1981 | Daniel | 4,646,756 A | 3/1987 | Watmough |
| 4,315,514 A | 2/1982 | Drewes et al. | 4,663,358 A | 5/1987 | Hyon |
| 4,325,381 A | 4/1982 | Glenn | 4,668,516 A | 5/1987 | Duraffourd et al. |
| 4,343,301 A | 8/1982 | Indech | 4,672,591 A | 6/1987 | Breimesser et al. |
| 4,372,296 A | 2/1983 | Fahim | 4,680,499 A | 7/1987 | Umemura et al. |
| 4,379,145 A | 4/1983 | Masuho et al. | 4,697,588 A | 10/1987 | Reichenberger |
| 4,381,007 A | 4/1983 | Doss | 4,754,760 A | 7/1988 | Fukukita et al. |
| 4,381,787 A | 5/1983 | Hottinger | 4,757,820 A | 7/1988 | Itoh |
| 4,397,314 A | 8/1983 | Vaguine | 4,771,205 A | 9/1988 | Mequio |
| 4,409,839 A | 10/1983 | Taenzer | 4,801,459 A | 1/1989 | Liburdy |
| 4,431,008 A | 2/1984 | Wanner et al. | 4,803,625 A | 2/1989 | Fu et al. |
| 4,441,486 A | 4/1984 | Pounds | 4,807,633 A | 2/1989 | Fry |
| 4,452,084 A | 6/1984 | Taenzer | 4,817,615 A | 4/1989 | Fukukita et al. |
| 4,484,569 A | 11/1984 | Driller | 4,858,613 A | 8/1989 | Fry |
| 4,507,582 A | 3/1985 | Glenn | 4,860,732 A | 8/1989 | Hasegawa et al. |
| | | | 4,865,041 A | 9/1989 | Hassler |
| | | | 4,865,042 A | 9/1989 | Umemura |
| | | | 4,867,169 A | 9/1989 | Machida |
| | | | 4,874,562 A | 10/1989 | Hyon |
| | | | 4,875,487 A | 10/1989 | Seppi |
| | | | 4,881,212 A | 11/1989 | Takeuchi |
| | | | 4,891,043 A | 1/1990 | Zeimer et al. |
| | | | 4,893,624 A | 1/1990 | Lele |
| | | | 4,896,673 A | 1/1990 | Rose |
| | | | 4,900,540 A | 2/1990 | Ryan et al. |
| | | | 4,901,729 A | 2/1990 | Saitoh |
| | | | 4,917,096 A | 4/1990 | Englehart |
| | | | 4,932,414 A | 6/1990 | Coleman et al. |
| | | | 4,938,216 A | 7/1990 | Lele |
| | | | 4,938,217 A | 7/1990 | Lele |
| | | | 4,947,046 A | 8/1990 | Kawabata et al. |
| | | | 4,951,653 A | 8/1990 | Fry |
| | | | 4,955,365 A | 9/1990 | Fry |
| | | | 4,958,626 A | 9/1990 | Nambu |
| | | | 4,976,709 A | 12/1990 | Sand |
| | | | 4,979,501 A | 12/1990 | Valchanov |
| | | | 4,992,989 A | 2/1991 | Watanabe et al. |
| | | | 5,012,797 A | 5/1991 | Liang |
| | | | 5,018,508 A | 5/1991 | Fry et al. |
| | | | 5,030,874 A | 7/1991 | Saito et al. |
| | | | 5,036,855 A | 8/1991 | Fry |
| | | | 5,040,537 A | 8/1991 | Katakura |
| | | | 5,054,310 A | 10/1991 | Flynn |
| | | | 5,054,470 A | 10/1991 | Fry |
| | | | 5,054,491 A | 10/1991 | Saito et al. |
| | | | 5,070,879 A | 12/1991 | Herres |
| | | | 5,088,495 A | 2/1992 | Miyagawa |
| | | | 5,115,814 A | 5/1992 | Griffith |
| | | | 5,117,832 A | 6/1992 | Sanghvi |
| | | | 5,123,418 A | 6/1992 | Saurel |
| | | | 5,142,511 A | 8/1992 | Kanai et al. |
| | | | 5,143,063 A | 9/1992 | Fellner |
| | | | 5,143,074 A | 9/1992 | Dory |
| | | | 5,149,319 A | 9/1992 | Unger |
| | | | 5,150,711 A | 9/1992 | Dory |
| | | | 5,150,714 A | 9/1992 | Green |
| | | | 5,152,294 A | 10/1992 | Mochizuki et al. |
| | | | 5,156,144 A | 10/1992 | Iwasaki |
| | | | 5,158,536 A | 10/1992 | Sekins |
| | | | 5,159,931 A | 11/1992 | Pini |
| | | | 5,163,421 A | 11/1992 | Bernstein |
| | | | 5,163,436 A | 11/1992 | Saitoh et al. |
| | | | 5,178,135 A | 1/1993 | Uchiyama et al. |
| | | | 5,190,518 A | 3/1993 | Takasu |
| | | | 5,190,766 A | 3/1993 | Ishihara |
| | | | 5,191,880 A | 3/1993 | McLeod |
| | | | 5,205,287 A | 4/1993 | Erbel et al. |
| | | | 5,209,720 A | 5/1993 | Unger |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|---------------|---------|------------------------------------|---------------|---------|--------------------------------------|
| 5,212,671 A | 5/1993 | Fujii et al. | 5,560,362 A | 10/1996 | Sliwa et al. |
| 5,215,680 A | 6/1993 | D'Arrigo | 5,573,497 A | 11/1996 | Chapelon |
| 5,224,467 A | 7/1993 | Oku | 5,575,291 A | 11/1996 | Hayakawa |
| 5,230,334 A | 7/1993 | Klopotek | 5,575,807 A | 11/1996 | Faller |
| 5,230,338 A | 7/1993 | Allen et al. | 5,577,502 A | 11/1996 | Darrow et al. |
| 5,247,924 A | 9/1993 | Suzuki et al. | 5,577,507 A | 11/1996 | Snyder et al. |
| 5,255,681 A | 10/1993 | Ishimura et al. | 5,577,991 A | 11/1996 | Akui et al. |
| 5,257,970 A | 11/1993 | Dougherty | 5,580,575 A | 12/1996 | Unger et al. |
| 5,265,614 A | 11/1993 | Hayakawa | 5,601,526 A * | 2/1997 | Chapelon A61N 7/02 601/2 |
| 5,267,985 A | 12/1993 | Shimada | 5,603,323 A | 2/1997 | Pflugrath et al. |
| 5,269,297 A | 12/1993 | Weng | 5,605,154 A * | 2/1997 | Ries G01S 7/52046 600/444 |
| 5,282,797 A | 2/1994 | Chess | 5,609,562 A | 3/1997 | Kaali |
| 5,295,484 A | 3/1994 | Marcus | 5,615,091 A | 3/1997 | Palatnik |
| 5,295,486 A | 3/1994 | Wollschlager et al. | 5,618,275 A | 4/1997 | Bock |
| 5,304,169 A | 4/1994 | Sand | 5,620,479 A | 4/1997 | Diederich |
| 5,305,756 A | 4/1994 | Entrekin et al. | 5,622,175 A | 4/1997 | Sudol et al. |
| 5,321,520 A | 6/1994 | Inga et al. | 5,617,858 A | 5/1997 | Taverna et al. |
| 5,323,779 A | 6/1994 | Hardy et al. | 5,638,819 A | 6/1997 | Manwaring et al. |
| 5,327,895 A | 7/1994 | Hashimoto et al. | 5,643,179 A * | 7/1997 | Fujimoto A61N 7/02 601/2 |
| 5,329,202 A | 7/1994 | Garlick et al. | 5,644,085 A | 7/1997 | Lorraine et al. |
| 5,348,016 A | 9/1994 | Unger et al. | 5,647,373 A | 7/1997 | Paltieli |
| 5,358,466 A * | 10/1994 | Aida A61B 17/2256 600/439 | 5,655,535 A | 8/1997 | Frlemel et al. |
| 5,360,268 A | 11/1994 | Hayashi | 5,655,538 A | 8/1997 | Lorraine |
| 5,370,121 A | 12/1994 | Reichenberger | 5,657,760 A | 8/1997 | Ying |
| 5,370,122 A | 12/1994 | Kunig | 5,658,328 A | 8/1997 | Johnson |
| 5,371,483 A | 12/1994 | Bhardwaj | 5,660,836 A * | 8/1997 | Knowlton A61B 18/12 128/898 |
| 5,375,602 A | 12/1994 | Lancee et al. | 5,662,116 A | 9/1997 | Kondo |
| 5,379,773 A | 1/1995 | Hornsby | 5,665,053 A | 9/1997 | Jacobs |
| 5,380,280 A | 1/1995 | Peterson | 5,665,141 A | 9/1997 | Vago |
| 5,380,519 A | 1/1995 | Schneider et al. | 5,671,746 A | 9/1997 | Dreschel et al. |
| 5,383,917 A | 1/1995 | Desai et al. | 5,673,699 A | 10/1997 | Trahey et al. |
| 5,391,140 A | 2/1995 | Schaetzle et al. | 5,676,692 A | 10/1997 | Sanghvi |
| 5,391,197 A | 2/1995 | Burdette et al. | 5,685,820 A | 11/1997 | Riek et al. |
| 5,392,259 A | 2/1995 | Bolorforosh | 5,690,608 A | 11/1997 | Watanabe |
| 5,396,143 A | 3/1995 | Seyed-Bolorforosh et al. | 5,694,936 A | 12/1997 | Fujimoto |
| 5,398,689 A | 3/1995 | Connor et al. | 5,697,897 A | 12/1997 | Buchholtz |
| 5,406,503 A | 4/1995 | Williams | 5,701,900 A | 12/1997 | Shehada et al. |
| 5,413,550 A * | 5/1995 | Castel A61H 23/0245 601/2 | 5,704,361 A | 1/1998 | Seward et al. |
| 5,417,216 A | 5/1995 | Tanaka | 5,706,252 A | 1/1998 | Le Verrier et al. |
| 5,423,220 A | 6/1995 | Finsterwald et al. | 5,706,564 A | 1/1998 | Rhyne |
| 5,435,311 A | 7/1995 | Umemura | 5,715,823 A | 2/1998 | Wood et al. |
| 5,438,998 A | 8/1995 | Hanafy | 5,720,287 A | 2/1998 | Chapelon et al. |
| 5,443,068 A * | 8/1995 | Cline A61B 5/0555 600/411 | 5,722,411 A | 3/1998 | Suzuki |
| 5,445,611 A | 8/1995 | Eppstein et al. | 5,727,554 A | 3/1998 | Kalend et al. |
| 5,458,596 A | 10/1995 | Lax | 5,735,280 A | 4/1998 | Sherman et al. |
| 5,460,179 A | 10/1995 | Okunuki et al. | 5,743,863 A | 4/1998 | Chapelon |
| 5,460,595 A | 10/1995 | Hall et al. | 5,746,005 A | 5/1998 | Steinberg |
| 5,419,327 A | 11/1995 | Rohwedder | 5,746,762 A | 5/1998 | Bass |
| 5,469,854 A | 11/1995 | Unger et al. | 5,748,767 A | 5/1998 | Raab |
| 5,471,488 A | 12/1995 | Fujio | 5,749,364 A | 5/1998 | Sliwa et al. |
| 5,472,405 A | 12/1995 | Buchholtz et al. | 5,755,228 A | 5/1998 | Wilson et al. |
| 5,487,388 A | 1/1996 | Rello et al. | 5,755,753 A | 5/1998 | Knowlton |
| 5,492,126 A | 2/1996 | Hennige | 5,762,066 A | 6/1998 | Law |
| 5,496,256 A | 3/1996 | Bock | 5,763,886 A | 6/1998 | Schulte |
| 5,501,655 A | 3/1996 | Rolt | 5,769,790 A | 6/1998 | Watkins |
| 5,503,152 A | 4/1996 | Oakley et al. | 5,779,644 A | 7/1998 | Eberle et al. |
| 5,503,320 A | 4/1996 | Webster et al. | 5,792,058 A | 8/1998 | Lee |
| 5,507,790 A | 4/1996 | Weiss | 5,795,297 A | 8/1998 | Daigle |
| 5,511,296 A | 4/1996 | Dias et al. | 5,795,311 A | 8/1998 | Wess |
| 5,520,188 A | 5/1996 | Hennige | 5,810,009 A | 9/1998 | Mine et al. |
| 5,522,869 A | 6/1996 | Burdette | 5,810,888 A | 9/1998 | Fenn |
| 5,523,058 A | 6/1996 | Umemura et al. | 5,814,599 A | 9/1998 | Mitragotri et al. |
| 5,524,620 A | 6/1996 | Rosenchein | 5,817,013 A | 10/1998 | Ginn et al. |
| 5,524,624 A | 6/1996 | Tepper | 5,817,021 A | 10/1998 | Reichenberger |
| 5,524,625 A | 6/1996 | Okazaki | 5,820,564 A | 10/1998 | Slayton |
| 5,526,624 A | 6/1996 | Berg | 5,823,962 A | 10/1998 | Schaetzle |
| 5,526,812 A | 6/1996 | Dumoulin et al. | 5,827,204 A | 10/1998 | Grandia et al. |
| 5,526,814 A | 6/1996 | Cline et al. | 5,840,032 A | 11/1998 | Hatfield et al. |
| 5,526,815 A | 6/1996 | Granz | 5,844,140 A | 12/1998 | Seale |
| 5,529,070 A | 6/1996 | Augustine et al. | 5,853,367 A | 12/1998 | Chalek et al. |
| 5,540,235 A | 7/1996 | Wilson | 5,869,751 A | 2/1999 | Bonin |
| 5,558,092 A | 9/1996 | Unger | 5,871,524 A | 2/1999 | Knowlton |
| | | | 5,873,902 A | 2/1999 | Sanghvi |
| | | | 5,876,341 A | 3/1999 | Wang et al. |
| | | | 5,879,303 A | 3/1999 | Averkiou et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|---------------|---------|---------------------------------------|----------------|---------|--------------------------------------|
| 5,882,557 A | 3/1999 | Hayakawa | 6,213,948 B1 | 4/2001 | Barthe |
| 5,891,034 A | 4/1999 | Bucholz | 6,216,029 B1 | 4/2001 | Paltieli |
| 5,895,356 A | 4/1999 | Andrus et al. | 6,233,476 B1 | 5/2001 | Strommer et al. |
| 5,899,861 A | 5/1999 | Friemel et al. | 6,234,990 B1 | 5/2001 | Rowe et al. |
| 5,904,659 A | 5/1999 | Duarte | 6,241,753 B1 * | 6/2001 | Knowlton A61B 18/12 128/898 |
| 5,919,219 A | 7/1999 | Knowlton | 6,246,898 B1 | 6/2001 | Vesely et al. |
| 5,923,099 A | 7/1999 | Bilir | 6,251,074 B1 | 6/2001 | Averkiou et al. |
| 5,924,989 A | 7/1999 | Polz | 6,251,088 B1 | 6/2001 | Kaufman et al. |
| 5,928,169 A | 7/1999 | Schatzle et al. | 6,268,405 B1 | 7/2001 | Yao |
| 5,931,805 A | 8/1999 | Briskin | 6,273,864 B1 | 8/2001 | Duarte |
| 5,938,606 A | 8/1999 | Bonnefous | 6,280,402 B1 | 8/2001 | Ishibashi et al. |
| 5,938,612 A | 8/1999 | Kline-Schoder | 6,287,257 B1 | 9/2001 | Maticchuk |
| 5,948,011 A | 9/1999 | Knowlton | 6,287,304 B1 | 9/2001 | Eggers et al. |
| 5,957,844 A | 9/1999 | Dekel | 6,296,619 B1 | 10/2001 | Briskin |
| 5,957,882 A | 9/1999 | Nita et al. | 6,301,989 B1 | 10/2001 | Brown et al. |
| 5,957,941 A | 9/1999 | Ream | 6,307,302 B1 | 10/2001 | Toda |
| 5,964,707 A | 10/1999 | Fenster et al. | 6,309,355 B1 | 10/2001 | Cain et al. |
| 5,967,980 A | 10/1999 | Ferre et al. | 6,311,090 B1 | 10/2001 | Knowlton |
| 5,968,034 A | 10/1999 | Fullmer | 6,315,741 B1 * | 11/2001 | Martin A61B 8/4254 601/3 |
| 5,971,949 A | 10/1999 | Levin | 6,322,509 B1 | 11/2001 | Pan et al. |
| 5,977,538 A | 11/1999 | Unger et al. | 6,322,532 B1 | 11/2001 | D'Sa |
| 5,984,881 A * | 11/1999 | Ishibashi A61B 17/2256 601/2 | 6,325,540 B1 | 12/2001 | Lounsberry et al. |
| 5,984,882 A | 11/1999 | Rosenchein | 6,325,758 B1 | 12/2001 | Carol et al. |
| 5,990,598 A | 11/1999 | Sudol et al. | 6,325,769 B1 | 12/2001 | Klopotek |
| 5,997,471 A | 12/1999 | Gumb et al. | 6,325,798 B1 | 12/2001 | Edwards et al. |
| 5,997,497 A | 12/1999 | Nita et al. | 6,338,716 B1 | 1/2002 | Hossack et al. |
| 5,999,843 A | 12/1999 | Anbar | 6,350,276 B1 | 2/2002 | Knowlton |
| 6,004,262 A | 12/1999 | Putz et al. | 6,356,780 B1 | 3/2002 | Licato et al. |
| 6,007,499 A | 12/1999 | Martin et al. | 6,361,531 B1 | 3/2002 | Hissong |
| 6,013,032 A | 1/2000 | Savord | 6,370,411 B1 | 4/2002 | Osadchy et al. |
| 6,014,473 A | 1/2000 | Hossack et al. | 6,375,672 B1 | 4/2002 | Aksan |
| 6,016,255 A | 1/2000 | Bolan et al. | 6,377,854 B1 | 4/2002 | Knowlton |
| 6,019,724 A | 2/2000 | Gronningsaeter et al. | 6,377,855 B1 | 4/2002 | Knowlton |
| 6,022,308 A | 2/2000 | Williams | 6,381,497 B1 | 4/2002 | Knowlton |
| 6,022,317 A | 2/2000 | Cruanas et al. | 6,381,498 B1 | 4/2002 | Knowlton |
| 6,022,327 A | 2/2000 | Chang | 6,387,380 B1 | 5/2002 | Knowlton |
| 6,030,374 A | 2/2000 | McDaniel | 6,390,982 B1 | 5/2002 | Bova et al. |
| 6,036,646 A | 3/2000 | Barthe | 6,405,090 B1 | 6/2002 | Knowlton |
| 6,039,048 A | 3/2000 | Silberg | 6,409,720 B1 | 6/2002 | Hissong |
| 6,039,689 A | 3/2000 | Lizzi | 6,413,216 B1 | 7/2002 | Cain et al. |
| 6,042,556 A * | 3/2000 | Beach A61N 7/02 600/437 | 6,413,253 B1 | 7/2002 | Koop |
| 6,049,159 A | 4/2000 | Barthe | 6,413,254 B1 | 7/2002 | Hissong |
| 6,050,943 A | 4/2000 | Slayton | 6,419,648 B1 | 7/2002 | Vitek |
| 6,059,727 A | 5/2000 | Fowlkes | 6,423,007 B2 | 7/2002 | Lizzi et al. |
| 6,071,239 A | 6/2000 | Cribbs | 6,425,865 B1 | 7/2002 | Salcudean |
| 6,080,108 A | 6/2000 | Dunham | 6,425,867 B1 | 7/2002 | Vaezy |
| 6,083,148 A | 7/2000 | Williams | 6,425,912 B1 | 7/2002 | Knowlton |
| 6,086,535 A | 7/2000 | Ishibashi | 6,428,477 B1 | 8/2002 | Mason |
| 6,086,580 A | 7/2000 | Mordon et al. | 6,428,532 B1 | 8/2002 | Doukas |
| 6,090,054 A | 7/2000 | Tagishi | 6,430,446 B1 | 8/2002 | Knowlton |
| 6,093,148 A * | 7/2000 | Fujimoto A61N 7/00 600/438 | 6,432,057 B1 | 8/2002 | Mazess et al. |
| 6,093,883 A | 7/2000 | Sanghvi | 6,432,067 B1 | 8/2002 | Martin |
| 6,101,407 A | 8/2000 | Groezienger | 6,432,101 B1 | 8/2002 | Weber |
| 6,106,469 A | 8/2000 | Suzuki et al. | 6,436,061 B1 | 8/2002 | Costantino |
| 6,113,558 A | 9/2000 | Rosenchein | 6,438,424 B1 | 8/2002 | Knowlton |
| 6,113,559 A | 9/2000 | Klopotek | 6,440,071 B1 | 8/2002 | Slayton |
| 6,120,452 A | 9/2000 | Barthe | 6,440,121 B1 | 8/2002 | Weber |
| 6,123,081 A | 9/2000 | Durette | 6,443,914 B1 | 9/2002 | Costantino |
| 6,126,619 A | 10/2000 | Peterson et al. | 6,447,443 B1 | 9/2002 | Keogh et al. |
| 6,135,971 A | 10/2000 | Hutchinson | 6,451,013 B1 | 9/2002 | Bays et al. |
| 6,139,499 A | 10/2000 | Wilk | 6,453,202 B1 | 9/2002 | Knowlton |
| 6,159,150 A | 12/2000 | Yale et al. | 6,461,304 B1 | 10/2002 | Tanaka et al. |
| 6,171,244 B1 | 1/2001 | Finger et al. | 6,461,378 B1 | 10/2002 | Knowlton |
| 6,176,840 B1 | 1/2001 | Nishimura | 6,470,216 B1 | 10/2002 | Knowlton |
| 6,183,426 B1 | 2/2001 | Akisada | 6,488,626 B1 | 12/2002 | Lizzi |
| 6,183,502 B1 | 2/2001 | Takeuchi | 6,491,657 B2 | 12/2002 | Rowe |
| 6,183,773 B1 | 2/2001 | Anderson | 6,500,121 B1 | 12/2002 | Slayton |
| 6,190,323 B1 | 2/2001 | Dias | 6,500,141 B1 | 12/2002 | Irion |
| 6,190,336 B1 | 2/2001 | Duarte | 6,506,171 B1 | 1/2003 | Vitek et al. |
| 6,193,658 B1 | 2/2001 | Wendelken | 6,508,774 B1 | 1/2003 | Acker |
| 6,198,956 B1 | 3/2001 | Dunne | 6,511,427 B1 | 1/2003 | Sliwa, Jr. et al. |
| 6,210,327 B1 | 4/2001 | Brackett et al. | 6,511,428 B1 | 1/2003 | Azuma |
| | | | 6,514,244 B2 | 2/2003 | Pope |
| | | | 6,517,484 B1 | 2/2003 | Wilk |
| | | | 6,524,250 B1 | 2/2003 | Weber |
| | | | 6,666,835 B2 | 3/2003 | Martin |
| | | | 6,540,679 B2 | 4/2003 | Slayton |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|-----------|----|---------|----------------------|-----------|----|---------|-------------------|
| 6,540,685 | B1 | 4/2003 | Rhoads et al. | 7,122,029 | B2 | 10/2006 | Koop et al. |
| 6,540,700 | B1 | 4/2003 | Fujimoto et al. | 7,142,905 | B2 | 11/2006 | Slayton |
| 6,547,788 | B1 | 4/2003 | Maguire et al. | 7,165,451 | B1 | 1/2007 | Brooks et al. |
| 6,554,771 | B1 | 4/2003 | Buil et al. | 7,179,238 | B2 | 2/2007 | Hissong |
| 6,569,099 | B1 | 5/2003 | Babaev | 7,189,230 | B2 | 3/2007 | Knowlton |
| 6,569,108 | B2 | 5/2003 | Sarvazyan et al. | 7,229,411 | B2 | 6/2007 | Slayton |
| 6,572,552 | B2 | 6/2003 | Fukukita | 7,235,592 | B2 | 6/2007 | Muratoglu |
| 6,575,956 | B1 | 6/2003 | Brisken et al. | 7,258,674 | B2 | 8/2007 | Cribbs |
| 6,595,934 | B1 | 7/2003 | Hissong | 7,273,459 | B2 | 9/2007 | Desilets |
| 6,599,256 | B1 | 7/2003 | Acker | 7,294,125 | B2 | 11/2007 | Phalen et al. |
| 6,605,043 | B1 | 8/2003 | Dreschel | 7,297,117 | B2 | 11/2007 | Trucco |
| 6,605,080 | B1 | 8/2003 | Altshuler et al. | 7,303,555 | B2 | 12/2007 | Makin et al. |
| 6,607,498 | B2 | 8/2003 | Eshel | 7,311,679 | B2 | 12/2007 | Desilets et al. |
| 6,618,620 | B1 | 9/2003 | Freundlich et al. | 7,327,071 | B2 | 2/2008 | Nishiyama et al. |
| 6,623,430 | B1 | 9/2003 | Slayton | 7,331,951 | B2 | 2/2008 | Eshel et al. |
| 6,626,854 | B2 | 9/2003 | Friedman | 7,332,985 | B2 | 2/2008 | Larson et al. |
| 6,626,855 | B1 | 9/2003 | Weng | 7,338,434 | B1 | 3/2008 | Haarstad et al. |
| 6,638,226 | B2 | 10/2003 | He et al. | 7,347,855 | B2 | 3/2008 | Eshel |
| 6,645,150 | B2 | 11/2003 | Angelsen et al. | RE40,403 | E | 6/2008 | Cho et al. |
| 6,645,162 | B2 | 11/2003 | Friedman | 7,393,325 | B2 | 7/2008 | Barthe |
| 6,662,054 | B2 | 12/2003 | Kreindel | 7,398,116 | B2 | 7/2008 | Edwards |
| 6,663,627 | B2 | 12/2003 | Francischelli | 7,399,279 | B2 | 7/2008 | Abend et al. |
| 6,665,806 | B1 | 12/2003 | Shimizu | 7,491,171 | B2 | 2/2009 | Barthe et al. |
| 6,669,638 | B1 | 12/2003 | Miller | 7,507,235 | B2 | 3/2009 | Keogh et al. |
| 6,685,639 | B1 | 2/2004 | Wang et al. | 7,510,536 | B2 | 3/2009 | Foley et al. |
| 6,685,640 | B1 | 2/2004 | Fry | 7,517,315 | B2 | 4/2009 | Willis |
| 6,692,450 | B1 | 2/2004 | Coleman | 7,530,356 | B2 | 5/2009 | Slayton |
| 6,699,237 | B2 | 3/2004 | Weber | 7,530,958 | B2 | 5/2009 | Slayton |
| 6,716,184 | B2 | 4/2004 | Vaezy et al. | 7,532,201 | B2 | 5/2009 | Quistgaard et al. |
| 6,719,449 | B1 | 4/2004 | Laughlin | 7,571,336 | B2 | 8/2009 | Barthe |
| 6,719,694 | B2 | 4/2004 | Weng | 7,601,120 | B2 | 10/2009 | Moilanen et al. |
| 6,726,627 | B1 | 4/2004 | Lizzi et al. | 7,615,015 | B2 | 11/2009 | Coleman |
| 6,733,449 | B1 | 5/2004 | Krishnamurthy et al. | 7,615,016 | B2 | 11/2009 | Barthe |
| 6,749,624 | B2 | 6/2004 | Knowlton | 7,652,411 | B2 | 1/2010 | Crunkilton et al. |
| 6,772,490 | B2 | 8/2004 | Toda | 7,662,114 | B2 | 2/2010 | Seip et al. |
| 6,773,409 | B2 | 8/2004 | Truckai et al. | 7,674,257 | B2 | 3/2010 | Pless et al. |
| 6,775,404 | B1 | 8/2004 | Pagoulatos et al. | 7,686,763 | B2 | 3/2010 | Vaezy et al. |
| 6,790,187 | B2 | 9/2004 | Thompson et al. | 7,713,203 | B2 | 3/2010 | Lacoste et al. |
| 6,824,516 | B2 | 11/2004 | Batten et al. | 7,694,406 | B2 | 4/2010 | Wildes et al. |
| 6,825,176 | B2 | 11/2004 | White et al. | 7,695,437 | B2 | 4/2010 | Quistgaard et al. |
| 6,835,940 | B2 | 12/2004 | Morikawa et al. | 7,727,156 | B2 | 6/2010 | Angelsen et al. |
| 6,846,290 | B2 | 1/2005 | Lizzi et al. | 7,758,524 | B2 | 7/2010 | Barthe |
| 6,875,176 | B2 | 4/2005 | Mourad et al. | 7,766,848 | B2 | 8/2010 | Desilets et al. |
| 6,882,884 | B1 | 4/2005 | Mosk et al. | 7,789,841 | B2 | 9/2010 | Huckle et al. |
| 6,887,239 | B2 | 5/2005 | Elstrom | 7,806,839 | B2 | 10/2010 | Mast et al. |
| 6,889,089 | B2 | 5/2005 | Behl | 7,815,570 | B2 | 10/2010 | Eshel et al. |
| 6,896,657 | B2 | 5/2005 | Willis | 7,819,826 | B2 | 10/2010 | Diederich et al. |
| 6,902,536 | B2 | 6/2005 | Manna | 7,828,734 | B2 | 10/2010 | Azhari et al. |
| 6,905,466 | B2 | 6/2005 | Salgo | 7,824,348 | B2 | 11/2010 | Barthe |
| 6,918,907 | B2 | 7/2005 | Kelly | 7,833,162 | B2 | 11/2010 | Hasegawa et al. |
| 6,920,883 | B2 | 7/2005 | Bessette | 7,841,984 | B2 | 11/2010 | Cribbs et al. |
| 6,921,371 | B2 | 7/2005 | Wilson | 7,846,096 | B2 | 12/2010 | Mast et al. |
| 6,932,771 | B2 | 8/2005 | Whitmore | 7,857,773 | B2 | 12/2010 | Desilets et al. |
| 6,932,814 | B2 | 8/2005 | Wood | 7,875,023 | B2 | 1/2011 | Eshel et al. |
| 6,936,044 | B2 | 8/2005 | McDaniel | 7,901,359 | B2 | 3/2011 | Mandrusov et al. |
| 6,936,046 | B2 | 8/2005 | Hissong | 7,905,007 | B2 | 3/2011 | Calisti et al. |
| 6,945,937 | B2 | 9/2005 | Culp et al. | 7,905,844 | B2 | 3/2011 | Desilets et al. |
| 6,948,843 | B2 | 9/2005 | Laugharn et al. | 7,914,453 | B2 | 3/2011 | Slayton et al. |
| 6,953,941 | B2 | 10/2005 | Nakano et al. | 7,914,469 | B2 | 3/2011 | Torbati |
| 6,958,043 | B2 | 10/2005 | Hissong | 7,955,281 | B2 | 6/2011 | Pedersen et al. |
| 6,971,994 | B1 | 12/2005 | Young et al. | 7,967,764 | B2 | 6/2011 | Lidgren et al. |
| 6,974,417 | B2 | 12/2005 | Lockwood | 7,967,839 | B2 | 6/2011 | Flock et al. |
| 6,976,492 | B2 | 12/2005 | Ingle | 7,955,262 | B2 | 7/2011 | Rosenberg |
| 6,992,305 | B2 | 1/2006 | Maezawa et al. | 7,993,289 | B2 | 8/2011 | Quistgaard et al. |
| 6,997,923 | B2 | 2/2006 | Anderson | 8,057,465 | B2 | 9/2011 | Sliwa, Jr. et al. |
| 7,006,874 | B2 | 2/2006 | Knowlton | 8,057,389 | B2 | 11/2011 | Barthe et al. |
| 7,020,528 | B2 | 3/2006 | Neev | 8,066,641 | B2 | 11/2011 | Barthe et al. |
| 7,022,089 | B2 | 4/2006 | Ooba | 8,123,707 | B2 | 2/2012 | Huckle et al. |
| 7,058,440 | B2 | 6/2006 | Heuscher et al. | 8,128,618 | B2 | 3/2012 | Gliklich et al. |
| 7,063,666 | B2 | 6/2006 | Weng | 8,133,180 | B2 | 3/2012 | Slayton et al. |
| 7,070,565 | B2 | 7/2006 | Vaezy et al. | 8,133,191 | B2 | 3/2012 | Rosenberg et al. |
| 7,074,218 | B2 | 7/2006 | Washington et al. | 8,142,200 | B2 | 3/2012 | Crunkilton et al. |
| 7,094,252 | B2 | 8/2006 | Koop | 8,152,904 | B2 | 4/2012 | Slobodgian et al. |
| 7,108,663 | B2 | 9/2006 | Talish et al. | 8,162,858 | B2 | 4/2012 | Manna et al. |
| 7,115,123 | B2 | 10/2006 | Knowlton | 8,166,332 | B2 | 4/2012 | Barthe et al. |
| | | | | 8,182,428 | B2 | 5/2012 | Angelsen et al. |
| | | | | 8,197,409 | B2 | 6/2012 | Foley et al. |
| | | | | 8,206,299 | B2 | 6/2012 | Foley et al. |
| | | | | 8,208,346 | B2 | 6/2012 | Crunkilton |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|--------------|---------|--------------------|-------------------|---------|------------------------------------|
| 8,211,017 B2 | 7/2012 | Foley et al. | 9,320,537 B2 | 4/2016 | Slayton et al. |
| 8,262,591 B2 | 9/2012 | Pedersen et al. | 9,345,910 B2 | 5/2016 | Slayton et al. |
| 8,262,650 B2 | 9/2012 | Zanelli et al. | 9,421,029 B2 | 8/2016 | Barthe et al. |
| 8,264,126 B2 | 9/2012 | Toda et al. | 9,427,600 B2 | 8/2016 | Barthe et al. |
| 8,273,037 B2 | 9/2012 | Kreindel et al. | 9,427,601 B2 | 8/2016 | Barthe et al. |
| 8,282,554 B2 | 10/2012 | Makin et al. | 9,433,803 B2 | 9/2016 | Lin et al. |
| 8,292,835 B1 | 10/2012 | Cimino | 9,440,093 B2 | 9/2016 | Homer |
| 8,298,163 B1 | 10/2012 | Cimino | 9,440,096 B2 | 9/2016 | Barthe et al. |
| 8,333,700 B1 | 12/2012 | Barthe et al. | 9,492,645 B2 | 11/2016 | Zhou et al. |
| 8,334,637 B2 | 12/2012 | Crunkilton et al. | 9,492,686 B2 | 11/2016 | Da Silva |
| 8,337,407 B2 | 12/2012 | Quistgaard et al. | 9,498,651 B2 | 11/2016 | Sapozhnikov et al. |
| 8,343,051 B2 | 1/2013 | Desilets et al. | 9,510,802 B2 | 12/2016 | Barthe et al. |
| 8,454,540 B2 | 1/2013 | Eshel et al. | 9,522,290 B2 | 12/2016 | Slayton et al. |
| 8,366,622 B2 | 2/2013 | Slayton et al. | 9,532,832 B2 | 1/2017 | Ron Edoute et al. |
| 8,398,549 B2 | 3/2013 | Palmeri et al. | 9,533,174 B2 | 1/2017 | Barthe et al. |
| 8,409,097 B2 | 4/2013 | Slayton et al. | 9,533,175 B2 | 1/2017 | Slayton et al. |
| 8,425,435 B2 | 4/2013 | Wing et al. | 9,545,529 B2 | 1/2017 | Britva et al. |
| 8,388,535 B2 | 5/2013 | Weng et al. | 9,566,454 B2 | 2/2017 | Barthe et al. |
| 8,444,562 B2 | 5/2013 | Barthe et al. | 9,623,267 B2 | 4/2017 | Ulric et al. |
| 8,460,193 B2 | 6/2013 | Barthe et al. | 9,694,211 B2 | 7/2017 | Barthe et al. |
| 8,480,585 B2 | 7/2013 | Slayton et al. | 9,694,212 B2 | 7/2017 | Barthe et al. |
| 8,486,001 B2 | 7/2013 | Weyant | 9,700,340 B2 | 7/2017 | Barthe et al. |
| 8,506,486 B2 | 8/2013 | Slayton et al. | 9,707,412 B2 | 7/2017 | Slayton et al. |
| 8,512,250 B2 | 8/2013 | Quistgaard et al. | 9,710,607 B2 | 7/2017 | Ramdas et al. |
| 8,523,775 B2 | 9/2013 | Barthe et al. | 9,713,731 B2 | 7/2017 | Slayton et al. |
| 8,523,849 B2 | 9/2013 | Liu et al. | 9,802,063 B2 | 10/2017 | Barthe et al. |
| 8,535,228 B2 | 9/2013 | Slayton et al. | 9,827,449 B2 | 11/2017 | Barthe et al. |
| 8,570,837 B2 | 10/2013 | Toda et al. | 9,827,450 B2 | 11/2017 | Slayton et al. |
| 8,573,392 B2 | 11/2013 | Bennett et al. | 9,833,639 B2 | 12/2017 | Slayton et al. |
| 8,583,211 B2 | 11/2013 | Salomir et al. | 9,833,640 B2 | 12/2017 | Barthe et al. |
| 8,585,618 B2 | 11/2013 | Hunziker et al. | 9,895,560 B2 | 2/2018 | Barthe et al. |
| 8,604,672 B2 | 12/2013 | Toda et al. | 9,907,535 B2 | 3/2018 | Barthe et al. |
| 8,622,937 B2 | 1/2014 | Weng et al. | 9,919,167 B2 | 3/2018 | Domankevitz |
| 8,636,665 B2 | 1/2014 | Slayton et al. | 9,974,982 B2 | 5/2018 | Slayton et al. |
| 8,641,622 B2 | 2/2014 | Barthe et al. | 1,001,072 A1 | 7/2018 | Slayton et al. |
| 8,663,112 B2 | 3/2014 | Slayton et al. | 1,004,618 A1 | 8/2018 | Barthe et al. |
| 8,672,848 B2 | 3/2014 | Slayton et al. | 2001/0009997 A1 | 7/2001 | Pope |
| 8,690,778 B2 | 4/2014 | Slayton et al. | 2001/0009999 A1 | 7/2001 | Kaufman et al. |
| 8,690,779 B2 | 4/2014 | Slayton et al. | 2001/0014780 A1 | 8/2001 | Martin |
| 8,690,780 B2 | 4/2014 | Slayton et al. | 2001/0014819 A1 | 8/2001 | Ingle |
| 8,708,935 B2 | 4/2014 | Barthe et al. | 2001/0031922 A1 * | 10/2001 | Weng A61B 17/0057 600/439 |
| 8,715,186 B2 | 5/2014 | Slayton et al. | 2001/0039380 A1 | 11/2001 | Larson et al. |
| 8,726,781 B2 | 5/2014 | Eckhoff et al. | 2001/0041880 A1 | 11/2001 | Briskin |
| 8,728,071 B2 | 5/2014 | Lischinsky et al. | 2002/0000763 A1 | 1/2002 | Jones |
| 8,753,295 B2 | 6/2014 | Thierman | 2002/0002345 A1 | 1/2002 | Marlinghaus |
| 8,758,253 B2 | 6/2014 | Sano et al. | 2002/0040199 A1 | 4/2002 | Klopotek |
| 8,836,203 B2 | 9/2014 | Nobles et al. | 2002/0040442 A1 | 4/2002 | Ishidera |
| 8,857,438 B2 | 10/2014 | Barthe et al. | 2002/0055702 A1 | 5/2002 | Atala |
| 8,858,471 B2 | 10/2014 | Barthe et al. | 2002/0062077 A1 | 5/2002 | Emmenegger |
| 8,915,853 B2 | 12/2014 | Barthe et al. | 2002/0062142 A1 | 5/2002 | Knowlton |
| 8,915,854 B2 | 12/2014 | Slayton et al. | 2002/0072691 A1 | 6/2002 | Thompson et al. |
| 8,915,870 B2 | 12/2014 | Barthe et al. | 2002/0082528 A1 | 6/2002 | Friedman |
| 8,920,320 B2 | 12/2014 | Stecco et al. | 2002/0082529 A1 | 6/2002 | Suorsa et al. |
| 8,920,324 B2 | 12/2014 | Slayton et al. | 2002/0082589 A1 | 6/2002 | Friedman |
| 8,926,533 B2 | 1/2015 | Bockenstedt et al. | 2002/0087080 A1 | 7/2002 | Slayton |
| 8,932,224 B2 | 1/2015 | Barthe et al. | 2002/0095143 A1 | 7/2002 | Key |
| 8,932,238 B2 | 1/2015 | Wing et al. | 2002/0099094 A1 | 7/2002 | Anderson |
| 8,968,205 B2 | 3/2015 | Zeng et al. | 2002/0115917 A1 | 8/2002 | Honda et al. |
| 9,011,336 B2 | 4/2015 | Slayton et al. | 2002/0128639 A1 | 8/2002 | Pless et al. |
| 9,039,617 B2 | 5/2015 | Slayton et al. | 2002/0128648 A1 | 9/2002 | Weber |
| 9,039,619 B2 | 5/2015 | Barthe et al. | 2002/0143252 A1 | 10/2002 | Dunne et al. |
| 9,050,116 B2 | 6/2015 | Homer | 2002/0156400 A1 | 10/2002 | Babaev |
| 9,095,697 B2 | 8/2015 | Barthe et al. | 2002/0161357 A1 | 10/2002 | Anderson |
| 9,107,798 B2 | 8/2015 | Azhari et al. | 2002/0165529 A1 | 11/2002 | Danek |
| 9,114,247 B2 | 8/2015 | Barthe et al. | 2002/0168049 A1 | 11/2002 | Schriever |
| 9,180,314 B2 | 11/2015 | Desilets et al. | 2002/0169394 A1 | 11/2002 | Eppstein et al. |
| 9,216,276 B2 | 12/2015 | Slayton et al. | 2002/0169442 A1 | 11/2002 | Neev |
| 9,220,915 B2 | 12/2015 | Liu et al. | 2002/0173721 A1 | 11/2002 | Grunwald et al. |
| 9,272,162 B2 | 3/2016 | Slayton et al. | 2002/0193784 A1 | 12/2002 | McHale et al. |
| 9,283,409 B2 | 3/2016 | Slayton et al. | 2002/0193831 A1 | 12/2002 | Smith |
| 9,283,410 B2 | 3/2016 | Slayton et al. | 2003/0009153 A1 | 1/2003 | Briskin et al. |
| 9,295,607 B2 | 3/2016 | Rosenberg | 2003/0014039 A1 | 1/2003 | Barzell et al. |
| 9,308,390 B2 | 4/2016 | Youngquist | 2003/0018255 A1 | 1/2003 | Martin |
| 9,308,391 B2 | 4/2016 | Liu et al. | 2003/0018270 A1 | 1/2003 | Makin et al. |
| 9,314,650 B2 | 4/2016 | Rosenberg et al. | 2003/0023283 A1 * | 1/2003 | McDaniel A61K 8/02 607/88 |
| | | | 2003/0028111 A1 | 2/2003 | Vaezy et al. |
| | | | 2003/0028113 A1 | 2/2003 | Gilbert et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | | | |
|--------------|----|---------|------------------|--------------|----|---------|-------------------|
| 2003/0032900 | A1 | 2/2003 | Ella | 2004/0217675 | A1 | 11/2004 | Desilets |
| 2003/0036706 | A1 | 2/2003 | Slayton et al. | 2004/0249318 | A1 | 12/2004 | Tanaka |
| 2003/0040739 | A1 | 2/2003 | Koop | 2004/0254620 | A1 | 12/2004 | Lacoste |
| 2003/0050678 | A1 | 3/2003 | Sierra | 2004/0267252 | A1 | 12/2004 | Washington et al. |
| 2003/0055308 | A1 | 3/2003 | Friemel et al. | 2005/0033201 | A1 | 2/2005 | Takahashi |
| 2003/0055417 | A1 | 3/2003 | Truckai et al. | 2005/0033316 | A1 | 2/2005 | Kertz |
| 2003/0060736 | A1 | 3/2003 | Martin et al. | 2005/0038340 | A1 | 2/2005 | Vaezy et al. |
| 2003/0065313 | A1 | 4/2003 | Koop | 2005/0055018 | A1 | 3/2005 | Kreindel |
| 2003/0066708 | A1 | 4/2003 | Allison et al. | 2005/0055073 | A1 | 3/2005 | Weber |
| 2003/0073907 | A1 | 4/2003 | Taylor | 2005/0061834 | A1 | 3/2005 | Garcia et al. |
| 2003/0074023 | A1 | 4/2003 | Kaplan | 2005/0070961 | A1 | 3/2005 | Maki |
| 2003/0083536 | A1 | 5/2003 | Eshel | 2005/0074407 | A1 | 4/2005 | Smith |
| 2003/0092988 | A1 | 5/2003 | Makin | 2005/0080469 | A1 | 4/2005 | Larson |
| 2003/0097071 | A1 | 5/2003 | Halmann et al. | 2005/0085731 | A1 | 4/2005 | Miller et al. |
| 2003/0099383 | A1 | 5/2003 | Lefebvre | 2005/0091770 | A1 | 5/2005 | Mourad et al. |
| 2003/0125629 | A1 | 7/2003 | Ustuner | 2005/0096542 | A1 | 5/2005 | Weng et al. |
| 2003/0135135 | A1 | 7/2003 | Miwa et al. | 2005/0104690 | A1 | 5/2005 | Larson et al. |
| 2003/0139790 | A1 | 7/2003 | Ingle et al. | 2005/0113689 | A1 | 5/2005 | Gritzky |
| 2003/0149366 | A1 | 8/2003 | Stringer et al. | 2005/0131302 | A1 | 6/2005 | Poland |
| 2003/0153961 | A1 | 8/2003 | Babaev | 2005/0137656 | A1 | 6/2005 | Malak |
| 2003/0171678 | A1 | 9/2003 | Batten et al. | 2005/0143677 | A1 | 6/2005 | Young et al. |
| 2003/0171701 | A1 | 9/2003 | Babaev | 2005/0154313 | A1 | 7/2005 | Desilets |
| 2003/0176790 | A1 | 9/2003 | Slayton | 2005/0154314 | A1 | 7/2005 | Quistgaard |
| 2003/0191396 | A1 | 10/2003 | Sanghvi | 2005/0154332 | A1 | 7/2005 | Zanelli |
| 2003/0199794 | A1 | 10/2003 | Sakurai et al. | 2005/0154431 | A1 | 7/2005 | Quistgaard |
| 2003/0200481 | A1 | 10/2003 | Stanley | 2005/0187495 | A1 | 8/2005 | Quistgaard |
| 2003/0212129 | A1 | 11/2003 | Liu et al. | 2005/0191252 | A1 | 9/2005 | Mitsui |
| 2003/0212351 | A1 | 11/2003 | Hissong | 2005/0193451 | A1 | 9/2005 | Quistgaard |
| 2003/0212393 | A1 | 11/2003 | Knowlton | 2005/0193820 | A1 | 9/2005 | Sheljaskow et al. |
| 2003/0216648 | A1 | 11/2003 | Lizzi et al. | 2005/0197681 | A1 | 9/2005 | Barolet et al. |
| 2003/0216795 | A1 | 11/2003 | Harth | 2005/0228281 | A1 | 10/2005 | Nefos |
| 2003/0220536 | A1 | 11/2003 | Hissong | 2005/0240127 | A1 | 10/2005 | Seip et al. |
| 2003/0220585 | A1 | 11/2003 | Hissong | 2005/0240170 | A1 | 10/2005 | Zhang et al. |
| 2003/0229331 | A1 | 12/2003 | Briskin et al. | 2005/0251120 | A1 | 11/2005 | Anderson et al. |
| 2003/0233085 | A1 | 12/2003 | Giammarusti | 2005/0251125 | A1 | 11/2005 | Pless et al. |
| 2003/0236487 | A1 | 12/2003 | Knowlton | 2005/0256406 | A1 | 11/2005 | Barthe |
| 2004/0000316 | A1 | 1/2004 | Knowlton | 2005/0261584 | A1 | 11/2005 | Eshel |
| 2004/0001809 | A1 | 1/2004 | Briskin | 2005/0261585 | A1 | 11/2005 | Makin et al. |
| 2004/0002658 | A1 | 1/2004 | Marian, Jr. | 2005/0267454 | A1 | 12/2005 | Hissong |
| 2004/0002705 | A1 | 1/2004 | Knowlton | 2005/0288748 | A1 | 12/2005 | Li et al. |
| 2004/0010222 | A1 | 1/2004 | Nunomura et al. | 2006/0004306 | A1 | 1/2006 | Altshuler |
| 2004/0015079 | A1 | 1/2004 | Berger et al. | 2006/0020260 | A1 | 1/2006 | Dover et al. |
| 2004/0015106 | A1 | 1/2004 | Coleman | 2006/0025756 | A1 | 2/2006 | Francischelli |
| 2004/0030227 | A1 | 2/2004 | Littrup | 2006/0042201 | A1 | 3/2006 | Curry |
| 2004/0030268 | A1 | 2/2004 | Weng et al. | 2006/0058664 | A1 | 3/2006 | Barthe |
| 2004/0039312 | A1 | 2/2004 | Hillstead | 2006/0058671 | A1 | 3/2006 | Vitek et al. |
| 2004/0039418 | A1 | 2/2004 | Elstrom | 2006/0058707 | A1 | 3/2006 | Barthe |
| 2004/0041563 | A1 | 3/2004 | Lewin et al. | 2006/0058712 | A1 | 3/2006 | Altshuler et al. |
| 2004/0041880 | A1 | 3/2004 | Ikeda et al. | 2006/0074309 | A1 | 4/2006 | Bonnefous |
| 2004/0042168 | A1 | 3/2004 | Yang et al. | 2006/0074313 | A1 | 4/2006 | Slayton et al. |
| 2004/0044375 | A1 | 3/2004 | Diederich et al. | 2006/0074314 | A1 | 4/2006 | Slayton |
| 2004/0049134 | A1 | 3/2004 | Tosaya et al. | 2006/0074355 | A1 | 4/2006 | Slayton |
| 2004/0049734 | A1 | 3/2004 | Tosaya et al. | 2006/0079816 | A1 | 4/2006 | Barthe |
| 2004/0059266 | A1 | 3/2004 | Fry | 2006/0079868 | A1 | 4/2006 | Makin |
| 2004/0068186 | A1 | 4/2004 | Ishida et al. | 2006/0084891 | A1 | 4/2006 | Barthe |
| 2004/0073079 | A1 | 4/2004 | Altshuler et al. | 2006/0089632 | A1 | 4/2006 | Barthe |
| 2004/0073113 | A1 | 4/2004 | Salgo | 2006/0089688 | A1 | 4/2006 | Panescu |
| 2004/0073115 | A1 | 4/2004 | Horzewski et al. | 2006/0094988 | A1 | 5/2006 | Tosaya |
| 2004/0073116 | A1 | 4/2004 | Smith | 2006/0111744 | A1 | 5/2006 | Makin |
| 2004/0073204 | A1 | 4/2004 | Ryan et al. | 2006/0116583 | A1 | 6/2006 | Ogasawara et al. |
| 2004/0077977 | A1 | 4/2004 | Ella et al. | 2006/0116671 | A1 | 6/2006 | Slayton |
| 2004/0082857 | A1 | 4/2004 | Schonenberger | 2006/0122508 | A1 | 6/2006 | Slayton |
| 2004/0082859 | A1 | 4/2004 | Schaer | 2006/0122509 | A1 | 6/2006 | Desilets |
| 2004/0102697 | A1 | 5/2004 | Evron | 2006/0161062 | A1 | 7/2006 | Arditi et al. |
| 2004/0105559 | A1 | 6/2004 | Aylward et al. | 2006/0184069 | A1 | 8/2006 | Vaitekunas |
| 2004/0106867 | A1 | 6/2004 | Eshel et al. | 2006/0184071 | A1 | 8/2006 | Klopotek |
| 2004/0122323 | A1 | 6/2004 | Vortman et al. | 2006/0189972 | A1 | 8/2006 | Grossman |
| 2004/0122493 | A1 | 6/2004 | Ishibashi et al. | 2006/0206105 | A1 | 9/2006 | Chopra |
| 2004/0143297 | A1 | 7/2004 | Ramsey | 2006/0224090 | A1 | 10/2006 | Ostrovsky et al. |
| 2004/0152982 | A1 | 8/2004 | Hwang et al. | 2006/0229514 | A1 | 10/2006 | Wiener |
| 2004/0158150 | A1 | 8/2004 | Rabiner et al. | 2006/0241440 | A1 | 10/2006 | Eshel |
| 2004/0186535 | A1 | 9/2004 | Knowlton | 2006/0241442 | A1 | 10/2006 | Barthe |
| 2004/0189155 | A1 | 9/2004 | Funakubo | 2006/0241470 | A1 | 10/2006 | Novak et al. |
| 2004/0206365 | A1 | 10/2004 | Knowlton | 2006/0241576 | A1 | 10/2006 | Diederich et al. |
| 2004/0210214 | A1 | 10/2004 | Knowlton | 2006/0250046 | A1 | 11/2006 | Koizumi et al. |
| | | | | 2006/0282691 | A1 | 12/2006 | Barthe |
| | | | | 2006/0291710 | A1 | 12/2006 | Wang et al. |
| | | | | 2007/0016039 | A1 | 1/2007 | Vortman et al. |
| | | | | 2007/0032784 | A1 | 2/2007 | Gliklich et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

| | | | | | |
|-----------------|---------|----------------------|-----------------|---------|---------------------|
| 2007/0035201 A1 | 2/2007 | Desilets | 2009/0318909 A1 | 12/2009 | Debenedictis et al. |
| 2007/0055154 A1 | 3/2007 | Torbati | 2009/0326420 A1 | 12/2009 | Moonen et al. |
| 2007/0055155 A1 | 3/2007 | Owen et al. | 2010/0011236 A1 | 1/2010 | Barthe et al. |
| 2007/0055156 A1 | 3/2007 | Desilets et al. | 2010/0022919 A1 | 1/2010 | Peterson |
| 2007/0065420 A1 | 3/2007 | Johnson | 2010/0022921 A1 | 1/2010 | Seip et al. |
| 2007/0083120 A1 | 4/2007 | Cain et al. | 2010/0022922 A1 | 1/2010 | Barthe et al. |
| 2007/0087060 A1 | 4/2007 | Dietrich | 2010/0030076 A1 | 2/2010 | Vortman et al. |
| 2007/0088245 A1 | 4/2007 | Babaev et al. | 2010/0042020 A1 | 2/2010 | Ben-Ezra |
| 2007/0088346 A1 | 4/2007 | Mirizzi et al. | 2010/0049178 A1 | 2/2010 | Deem et al. |
| 2007/0161902 A1 | 7/2007 | Dan | 2010/0056925 A1 | 3/2010 | Zhang et al. |
| 2007/0166357 A1 | 7/2007 | Shaffer et al. | 2010/0100014 A1 | 4/2010 | Eshel et al. |
| 2007/0167709 A1 | 7/2007 | Slayton | 2010/0113983 A1 | 5/2010 | Heckerman et al. |
| 2007/0208253 A1 | 9/2007 | Slayton | 2010/0130891 A1 | 5/2010 | Taggart et al. |
| 2007/0219604 A1 | 9/2007 | Yaroslavsky et al. | 2010/0160782 A1 | 6/2010 | Slayton et al. |
| 2007/0219605 A1 | 9/2007 | Yaroslavsky et al. | 2010/0160837 A1 | 6/2010 | Hunziker et al. |
| 2007/0238994 A1 | 10/2007 | Stecco et al. | 2010/0168576 A1 | 7/2010 | Poland et al. |
| 2007/0239075 A1 | 10/2007 | Rosenberg | 2010/0191120 A1 | 7/2010 | Kraus et al. |
| 2007/0239077 A1 | 10/2007 | Azhari et al. | 2010/0241035 A1 | 9/2010 | Barthe et al. |
| 2007/0239079 A1 | 10/2007 | Manstein et al. | 2010/0249602 A1 | 9/2010 | Buckley et al. |
| 2007/0239142 A1 | 10/2007 | Altshuler | 2010/0249669 A1 | 9/2010 | Ulric et al. |
| 2008/0015435 A1 | 1/2008 | Cribbs et al. | 2010/0256489 A1 | 10/2010 | Pedersen et al. |
| 2008/0027328 A1 | 1/2008 | Klopotek | 2010/0274161 A1 | 10/2010 | Azhari et al. |
| 2008/0039724 A1 | 2/2008 | Seip et al. | 2010/0280420 A1 | 11/2010 | Barthe et al. |
| 2008/0071255 A1 | 3/2008 | Barthe | 2010/0286518 A1 | 11/2010 | Lee et al. |
| 2008/0086054 A1 | 4/2008 | Slayton | 2010/0312150 A1 | 12/2010 | Douglas et al. |
| 2008/0086056 A1 | 4/2008 | Chang et al. | 2011/0040171 A1 | 2/2011 | Foley et al. |
| 2008/0097214 A1 | 4/2008 | Meyers et al. | 2011/0040190 A1 | 2/2011 | Jahnke et al. |
| 2008/0097253 A1 | 4/2008 | Pedersen et al. | 2011/0040213 A1 | 2/2011 | Dietz et al. |
| 2008/0114251 A1 | 5/2008 | Weymer | 2011/0040214 A1 | 2/2011 | Foley et al. |
| 2008/0139943 A1 | 6/2008 | Deng et al. | 2011/0066084 A1 | 3/2011 | Desilets et al. |
| 2008/0139974 A1 | 6/2008 | Da Silva | 2011/0077514 A1 | 3/2011 | Ulric et al. |
| 2008/0146970 A1 | 6/2008 | Litman et al. | 2011/0087099 A1 | 4/2011 | Eshel et al. |
| 2008/0167556 A1 | 7/2008 | Thompson | 2011/0087255 A1 | 4/2011 | McCormack et al. |
| 2008/0183077 A1 | 7/2008 | Moreau-Gobard et al. | 2011/0112405 A1 | 5/2011 | Barthe et al. |
| 2008/0183110 A1 | 7/2008 | Davenport et al. | 2011/0144490 A1 | 6/2011 | Davis et al. |
| 2008/0188745 A1 | 8/2008 | Chen et al. | 2011/0178444 A1 | 7/2011 | Slayton et al. |
| 2008/0194964 A1 | 8/2008 | Randall et al. | 2011/0178541 A1 | 7/2011 | Azhari |
| 2008/0195000 A1 | 8/2008 | Spooner et al. | 2011/0190745 A1 | 8/2011 | Uebelhoer et al. |
| 2008/0200810 A1 | 8/2008 | Buchalter | 2011/0201976 A1 | 8/2011 | Sanghvi et al. |
| 2008/0200813 A1 | 8/2008 | Quistgaard | 2011/0251524 A1 | 10/2011 | Azhari et al. |
| 2008/0214966 A1 | 9/2008 | Slayton | 2011/0251527 A1 | 10/2011 | Kushculey et al. |
| 2008/0214988 A1 | 9/2008 | Altshuler et al. | 2011/0270137 A1 | 11/2011 | Goren et al. |
| 2008/0221491 A1 | 9/2008 | Slayton | 2011/0319793 A1 | 12/2011 | Henrik et al. |
| 2008/0223379 A1 | 9/2008 | Stuker et al. | 2011/0319794 A1 | 12/2011 | Gertner |
| 2008/0242991 A1 | 10/2008 | Moon et al. | 2012/0004549 A1 | 1/2012 | Barthe et al. |
| 2008/0243035 A1 | 10/2008 | Crunkilton | 2012/0016239 A1 | 1/2012 | Barthe et al. |
| 2008/0269608 A1 | 10/2008 | Anderson et al. | 2012/0029353 A1 | 2/2012 | Slayton et al. |
| 2008/0275342 A1 | 11/2008 | Barthe | 2012/0035473 A1 | 2/2012 | Sanghvi et al. |
| 2008/0281206 A1 | 11/2008 | Bartlett et al. | 2012/0035475 A1 | 2/2012 | Barthe et al. |
| 2008/0281236 A1 | 11/2008 | Eshel et al. | 2012/0035476 A1 | 2/2012 | Barthe et al. |
| 2008/0281237 A1 | 11/2008 | Slayton | 2012/0046547 A1 | 2/2012 | Barthe et al. |
| 2008/0281255 A1 | 11/2008 | Slayton | 2012/0053458 A1 | 3/2012 | Barthe et al. |
| 2008/0294073 A1 | 11/2008 | Barthe | 2012/0059288 A1 | 3/2012 | Barthe et al. |
| 2008/0319356 A1 | 12/2008 | Cain | 2012/0111339 A1 | 5/2012 | Barthe et al. |
| 2009/0005680 A1 | 1/2009 | Jones et al. | 2012/0123304 A1 | 5/2012 | Rybyanets et al. |
| 2009/0012394 A1 | 1/2009 | Hobelsberger et al. | 2012/0136280 A1 | 5/2012 | Rosenberg et al. |
| 2009/0043198 A1 | 2/2009 | Milner et al. | 2012/0136282 A1 | 5/2012 | Rosenberg et al. |
| 2009/0043293 A1 | 2/2009 | Pankratov et al. | 2012/0143056 A1 | 6/2012 | Slayton et al. |
| 2009/0048514 A1 | 2/2009 | Azhari et al. | 2012/0143100 A1 | 6/2012 | Jeong et al. |
| 2009/0069677 A1 | 3/2009 | Chen et al. | 2012/0165668 A1 | 6/2012 | Slayton et al. |
| 2009/0093737 A1 | 4/2009 | Chomas et al. | 2012/0165848 A1 | 6/2012 | Slayton et al. |
| 2009/0156969 A1 | 6/2009 | Santangelo | 2012/0191019 A1 | 7/2012 | Desilets et al. |
| 2009/0163807 A1 | 6/2009 | Sliwa | 2012/0191020 A1 | 7/2012 | Vitek et al. |
| 2009/0171252 A1 | 7/2009 | Bockenstedt et al. | 2012/0197120 A1 | 8/2012 | Makin et al. |
| 2009/0177122 A1 | 7/2009 | Peterson | 2012/0197121 A1 | 8/2012 | Slayton et al. |
| 2009/0177123 A1 | 7/2009 | Peterson | 2012/0209150 A1 | 8/2012 | Zeng et al. |
| 2009/0182231 A1 | 7/2009 | Barthe et al. | 2012/0215105 A1 | 8/2012 | Slayton et al. |
| 2009/0198157 A1 | 8/2009 | Babaev et al. | 2012/0271202 A1 | 10/2012 | Wisdom |
| 2009/0216159 A1 | 8/2009 | Slayton et al. | 2012/0271294 A1 | 10/2012 | Barthe et al. |
| 2009/0226424 A1 | 9/2009 | Hsu | 2012/0296240 A1 | 11/2012 | Azhari et al. |
| 2009/0227910 A1 | 9/2009 | Pedersen et al. | 2012/0302883 A1 | 11/2012 | Kong et al. |
| 2009/0230823 A1 | 9/2009 | Kushculey et al. | 2012/0316426 A1 | 12/2012 | Foley et al. |
| 2009/0253988 A1 | 10/2009 | Slayton et al. | 2012/0330197 A1 | 12/2012 | Makin et al. |
| 2009/0281463 A1 | 11/2009 | Chapelon et al. | 2012/0330222 A1 | 12/2012 | Makin et al. |
| 2009/0312693 A1 | 12/2009 | Thapliyal et al. | 2012/0330223 A1 | 12/2012 | Makin et al. |
| | | | 2012/0330283 A1 | 12/2012 | Hyde et al. |
| | | | 2012/0330284 A1 | 12/2012 | Hyde et al. |
| | | | 2013/0012755 A1 | 1/2013 | Slayton |
| | | | 2013/0012816 A1 | 1/2013 | Slayton et al. |

(56)

References Cited

U.S. PATENT DOCUMENTS

2013/0012838 A1 1/2013 Jaeger et al.
 2013/0012842 A1 1/2013 Barthe
 2013/0018285 A1 1/2013 Park et al.
 2013/0018286 A1 1/2013 Slayton et al.
 2013/0046209 A1 2/2013 Slayton et al.
 2013/0051178 A1 2/2013 Rybyanets
 2013/0060170 A1 3/2013 Lee et al.
 2013/0066208 A1 3/2013 Barthe et al.
 2013/0066237 A1 3/2013 Smotrich et al.
 2013/0072826 A1 3/2013 Slayton et al.
 2013/0073001 A1 3/2013 Campbell
 2013/0096471 A1 4/2013 Slayton et al.
 2013/0190659 A1 7/2013 Slayton et al.
 2013/0211293 A1 8/2013 Auboiroux et al.
 2013/0225994 A1 8/2013 Hsu et al.
 2013/0268032 A1 10/2013 Neev
 2013/0274603 A1 10/2013 Barthe et al.
 2013/0281853 A1 10/2013 Slayton et al.
 2013/0281891 A1 10/2013 Slayton et al.
 2013/0296697 A1 11/2013 Slayton et al.
 2013/0296700 A1 11/2013 Slayton et al.
 2013/0296743 A1 11/2013 Lee et al.
 2013/0303904 A1 11/2013 Barthe et al.
 2013/0303905 A1 11/2013 Barthe et al.
 2013/0310714 A1 11/2013 Eshel et al.
 2013/0310863 A1 11/2013 Makin et al.
 2013/0345562 A1 12/2013 Barthe et al.
 2014/0024974 A1 1/2014 Slayton et al.
 2014/0050054 A1 2/2014 Toda et al.
 2014/0081300 A1 3/2014 Melodelima et al.
 2014/0082907 A1 3/2014 Barthe et al.
 2014/0117814 A1 5/2014 Toda et al.
 2014/0142430 A1 5/2014 Slayton et al.
 2014/0148834 A1 5/2014 Barthe et al.
 2014/0180174 A1 6/2014 Slayton et al.
 2014/0187944 A1 7/2014 Slayton et al.
 2014/0188015 A1 7/2014 Slayton et al.
 2014/0188145 A1 7/2014 Slayton et al.
 2014/0194723 A1 7/2014 Herzog et al.
 2014/0208856 A1 7/2014 Schmid
 2014/0221823 A1 8/2014 Keogh et al.
 2014/0236049 A1 8/2014 Barthe et al.
 2014/0236061 A1 8/2014 Lee et al.
 2014/0243713 A1 8/2014 Slayton et al.
 2014/0257145 A1 9/2014 Emery
 2014/0276055 A1 9/2014 Barthe et al.
 2015/0000674 A1 1/2015 Barthe et al.
 2015/0025420 A1 1/2015 Slayton et al.
 2015/0080723 A1 3/2015 Barthe et al.
 2015/0080771 A1 3/2015 Barthe et al.
 2015/0080874 A1 3/2015 Slayton et al.
 2015/0088182 A1 3/2015 Slayton et al.
 2015/0141734 A1 5/2015 Chapelon et al.
 2015/0164734 A1 6/2015 Slayton et al.
 2015/0165238 A1 6/2015 Slayton et al.
 2015/0165243 A1 6/2015 Slayton et al.
 2015/0174388 A1 6/2015 Slayton
 2015/0202468 A1 7/2015 Slayton et al.
 2015/0217141 A1 8/2015 Barthe et al.
 2015/0238258 A1 8/2015 Palero et al.
 2015/0321026 A1 11/2015 Branson et al.
 2015/0360058 A1 12/2015 Barthe et al.
 2015/0374333 A1 12/2015 Barthe et al.
 2015/0375014 A1 12/2015 Slayton et al.
 2016/0016015 A1 1/2016 Slayton et al.
 2016/0027994 A1 1/2016 Toda et al.
 2016/0151618 A1 6/2016 Powers et al.
 2016/0175619 A1 6/2016 Lee et al.
 2016/0206335 A1 7/2016 Slayton
 2016/0206341 A1 7/2016 Slayton
 2016/0256675 A1 9/2016 Slayton
 2016/0296769 A1 10/2016 Barthe et al.
 2016/0361571 A1 12/2016 Bernabei
 2016/0361572 A1 12/2016 Slayton
 2017/0028227 A1 2/2017 Emery et al.

2017/0043190 A1 2/2017 Barthe et al.
 2017/0050019 A1 2/2017 Ron Edoute et al.
 2017/0080257 A1 3/2017 Paunescu et al.
 2017/0100585 A1 4/2017 Hall et al.
 2017/0136263 A1 5/2017 Reil
 2017/0209201 A1 7/2017 Slayton et al.
 2017/0304654 A1 10/2017 Blanche et al.
 2018/0001113 A1 1/2018 Streeter
 2018/0015308 A1 1/2018 Reed et al.
 2018/0043147 A1 2/2018 Slayton
 2018/0099162 A1 4/2018 Bernabei
 2018/0099163 A1 4/2018 Bernabei

FOREIGN PATENT DOCUMENTS

DE 10140064 3/2003
 DE 10219297 11/2003
 DE 10219217 12/2004
 DE 20314479 12/2004
 EP 0142215 5/1984
 EP 0344773 12/1989
 EP 1479412 11/1991
 EP 0473553 4/1992
 EP 670147 2/1995
 EP 0661029 7/1995
 EP 724894 2/1996
 EP 763371 11/1996
 EP 1044038 10/2000
 EP 1050322 11/2000
 EP 1234566 8/2002
 EP 1262160 12/2002
 EP 0659387 4/2003
 EP 1374944 1/2004
 EP 1028660 1/2008
 EP 1874241 1/2008
 EP 1362223 5/2008
 EP 1750804 7/2008
 EP 1283690 11/2008
 EP 1811901 4/2009
 EP 1785164 8/2009
 EP 2230904 9/2010
 EP 1501331 6/2011
 EP 2066405 11/2011
 EP 2474050 7/2012
 EP 2709726 11/2015
 EP 1538980 1/2017
 EP 2897547 11/2017
 FR 2532851 9/1983
 FR 2685872 1/1992
 FR 2672486 8/1992
 FR 2703254 3/1994
 GB 2113099 8/1983
 IL 102516 1/1996
 IL 112369 8/1999
 IL 120079 3/2001
 JP 63036171 2/1988
 JP 03048299 3/1991
 JP 3123559 5/1991
 JP 03136642 6/1991
 JP 4089058 3/1992
 JP 04150847 5/1992
 JP 7080087 3/1995
 JP 07505793 6/1995
 JP 7184907 7/1995
 JP 7222782 8/1995
 JP 09047458 2/1997
 JP 9108288 4/1997
 JP 9503926 4/1997
 JP 11123226 5/1999
 JP 11505440 5/1999
 JP 11506636 6/1999
 JP 10248850 9/1999
 JP 2000126310 5/2000
 JP 2000166940 6/2000
 JP 2000233009 8/2000
 JP 2001170068 6/2001
 JP 2002505596 2/2002
 JP 2002078764 3/2002
 JP 2002515786 5/2002

(56) References Cited

FOREIGN PATENT DOCUMENTS

| | | |
|----|-----------------|---------|
| JP | 2002521118 | 7/2002 |
| JP | 2002537939 | 11/2002 |
| JP | 2003050298 | 7/2003 |
| JP | 2003204982 | 7/2003 |
| JP | 2004-504898 | 2/2004 |
| JP | 2004-507280 | 3/2004 |
| JP | 2004-509671 | 4/2004 |
| JP | 2004-512856 | 4/2004 |
| JP | 2004147719 | 5/2004 |
| JP | 2005503388 | 2/2005 |
| JP | 2005527336 | 9/2005 |
| JP | 2005532313 | 11/2005 |
| JP | 2006520247 | 9/2006 |
| JP | 2008515559 | 5/2008 |
| JP | 2009518126 | 5/2009 |
| JP | 2010517695 | 5/2010 |
| KR | 1020010024871 | 3/2001 |
| KR | 100400870 | 10/2003 |
| KR | 20060121267 | 11/2006 |
| KR | 1020060113930 | 11/2006 |
| KR | 1020070065332 | 6/2007 |
| KR | 1020070070161 | 7/2007 |
| KR | 1020070098856 | 10/2007 |
| KR | 1020070104878 | 10/2007 |
| KR | 1020070114105 | 11/2007 |
| KR | 1020000059516 | 4/2012 |
| KR | 10-2013-0124598 | 11/2013 |
| KR | 10-1365946 | 2/2014 |
| TW | 386883 | 9/2000 |
| TW | 201208734 A | 3/2012 |
| WO | WO9312742 | 7/1993 |
| WO | WO9524159 | 9/1995 |
| WO | WO9625888 | 8/1996 |
| WO | WO9634568 | 11/1996 |
| WO | WO9639079 | 12/1996 |
| WO | WO9735518 | 10/1997 |
| WO | WO9832379 | 7/1998 |
| WO | WO9852465 | 11/1998 |
| WO | WO9933520 | 7/1999 |
| WO | WO9949788 | 10/1999 |
| WO | WO200006032 | 2/2000 |
| WO | WO0015300 | 3/2000 |
| WO | WO0021612 | 4/2000 |
| WO | WO0053113 | 9/2000 |
| WO | WO0128623 | 4/2001 |
| WO | WO01045550 | 6/2001 |
| WO | WO0182777 | 11/2001 |
| WO | WO0182778 | 11/2001 |
| WO | WO0187161 | 11/2001 |
| WO | WO01080709 | 11/2001 |
| WO | WO2001087161 | 11/2001 |
| WO | WO0209812 | 2/2002 |
| WO | WO0209813 | 2/2002 |
| WO | WO02015768 | 2/2002 |
| WO | WO0224050 | 3/2002 |
| WO | WO2002054018 | 7/2002 |
| WO | WO02092168 | 11/2002 |
| WO | WO03053266 | 7/2003 |
| WO | WO03065347 | 8/2003 |
| WO | WO03070105 | 8/2003 |
| WO | WO03077833 | 9/2003 |
| WO | WO03086215 | 10/2003 |
| WO | WO03096883 | 11/2003 |
| WO | WO03099177 | 12/2003 |
| WO | WO03099382 | 12/2003 |
| WO | WO03101530 | 12/2003 |
| WO | WO2004000116 | 12/2003 |
| WO | WO2004080147 | 9/2004 |
| WO | WO2004110558 | 12/2004 |
| WO | WO2005/011804 | 2/2005 |
| WO | WO2005065408 | 7/2005 |
| WO | WO2005065409 | 7/2005 |
| WO | WO2005090978 | 9/2005 |
| WO | WO2005113068 | 12/2005 |
| WO | WO2006/042163 | 4/2006 |

| | | |
|----|--------------|---------|
| WO | WO2006036870 | 4/2006 |
| WO | WO2006042168 | 4/2006 |
| WO | WO2006042201 | 4/2006 |
| WO | WO2006065671 | 6/2006 |
| WO | WO2006082573 | 8/2006 |
| WO | WO2006104568 | 10/2006 |
| WO | WO2007067563 | 6/2007 |
| WO | WO2008036479 | 3/2008 |
| WO | WO2008036622 | 3/2008 |
| WO | WO2008144274 | 11/2008 |
| WO | WO2009013729 | 1/2009 |
| WO | WO2009149390 | 10/2009 |
| WO | WO2012134645 | 10/2012 |
| WO | WO2013048912 | 4/2013 |
| WO | WO2013178830 | 12/2013 |
| WO | WO2014045216 | 3/2014 |
| WO | WO2014055708 | 4/2014 |
| WO | WO2014057388 | 4/2014 |
| WO | WO2014127091 | 8/2014 |
| WO | WO2015160708 | 10/2015 |
| WO | WO2016054155 | 4/2016 |
| WO | WO2017127328 | 7/2017 |
| WO | WO2017149506 | 9/2017 |
| WO | WO2017165595 | 9/2017 |
| WO | WO2017212489 | 12/2017 |
| WO | WO2018035012 | 2/2018 |

OTHER PUBLICATIONS

Federal Circuit Order Granting Ulthera Motion to Remand, re: 2018-1542; 4 pages [022] (Dated May 25, 2018).

Agren, Magnus S. et al., Collagenase in Wound Healing: Effect of Wound Age and Type. *The Journal of Investigative Dermatology*, vol. 99/No. 6, (Dec. 1992).

Alam, M., "The future of noninvasive procedural dermatology". *Semin Cutan Med Surg.* Mar. 2013; 32(1):59-61.

Alam, M., et al., "Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study". *J Am Acad Dermatol*, 2010. 62(2): p. 262-9.

Alexiades-Armenakas, M., "Ultrasound Technologies for Dermatologic Techniques". *J Drugs Derm.* 2014. 12 (11): p. 1305.

Alster, T.S., et. al., "Noninvasive lifting of arm, thigh, and knee skin with transcutaneous intense focused ultrasound". *Dermatol Surg*, 2012. 38(5): p. 754-9.

Alster, Tinas S., Tanzi, Elizabeth L., "Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device," *Journal of Cosmetic & Laser Therapy*, Jun. 2005, vol. 7, Issue 2, pp. 81-85.

Arosarena, O., "Options and Challenges for Facial Rejuvenation in Patients With Higher Fitzpatrick Skin Phototypes". *JAMA Facial Plastic Surgery*, 2015.

Arthur et al., "Non-invasive estimation of hyperthermia temperatures with ultrasound," *Int. J. Hyperthermia*, Sep. 2005, 21(6), pp. 589-600.

Barthe et al., "Ultrasound therapy system and ablation results utilizing miniature imaging/therapy arrays," *Ultrasonics Symposium*, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.

Bozec, Laurent et al., Thermal Denaturation Studies of Collagen by Microthermal Analysis and Atomic Force Microscopy, *Biophysical Journal*, vol. 101, pp. 228-236. (Jul. 2001).

Brobst, R.W., et. al., "Noninvasive Treatment of the Neck". *Facial Plast Surg Clin North Am*, 2014. 22(2): p. 191-202.

Brobst, R.W., et., al., "Ulthera: initial and six month results". *Facial Plast Surg Clin North Am*, 2012. 20(2): p. 163-76.

Calderhead et al., "One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell" *Laser Therapy* 17.3: 141-148 (2008).

Carruthers et al., "Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices" *Dermatol Surg* 2016 (pp. 1-12).

Casabona, G., et. al., "Microfocused Ultrasound with Visualization and Calcium Hydroxylapatite for Improving Skin Laxity and Cellulite Appearance"; *Plast Reconstr Surg Glob Open*. Jul. 25, 2017;5(7):e1388, 8 pages.

(56)

References Cited

OTHER PUBLICATIONS

- Casabona, G., et. al., "Microfocused Ultrasound With Visualization and Fillers for Increased Neocollagenesis: Clinical and Histological Evaluation". *Dermatol Surg* 2014;40:S194-S198.
- Chan, N.P., et al "Safety study of transcutaneous focused ultrasound for non-invasive skin tightening Asians". *Lasers Surg Med*, 2011. 43(5): p. 366-75.
- Chapelon et al., "Effects of Cavitation in the High Intensity Therapeutic Ultrasound", *Ultrasonics Symposium—1357* (1991).
- Chapelon, et al., "Thresholds for Tissue Ablation by Focused Ultrasound" (1990).
- Chen, L. et al., "Effect of Blood Perfusion on the ablation of liver parenchyma with high intensity focused ultrasound," *Phys. Med. Biol.* 38:1661-1673; 1993b.
- Coon, Joshua et al., "Protein identification using sequential ion/ion reactions and tandem mass spectrometry" *Proceedings of the National Academy of Sciences of the USA*, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.
- Corry, Peter M., et al., "Human Cancer Treatment with Ultrasound", *IEEE Transactions on Sonics and Ultrasonics*, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456.
- Damianou et al., "Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery," 1993 *IEEE Ultrasound Symposium*, pp. 1199-1202.
- Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, *IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control*, vol. 45, No. 2, Mar. 1998, pp. 431-438.
- Davis, Brian J., et al., "An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues", 1985 *Ultrasonics Symposium*, pp. 921-924.
- Dayan, S.H., et al., "Prospective, Multi-Center, Pivotal Trial Evaluating the Safety and Effectiveness of Micro-Focused Ultrasound with Visualization (MFU-V) for Improvement in Lines and Wrinkles of the Décolletage". *Plast Reconstr Surg*. Oct. 2014; 134(4 Suppl 1):123-4.
- Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on pp. 1-4 of the Information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).
- Delon Martin, C., et al, "Venous Thrombosis Generation by Means of High-Intensity Focused Ultrasound" *Ultrasound in Med. & Biol.*, vol. 21, No. 1, pp. 113-119 (1995).
- Dierickx, Christine C., "The Role of Deep Heating for Noninvasive Skin Rejuvenation" *Lasers in Surgery and Medicine* 38:799-807 (2006).
- Dobke, M.K., et al., "Tissue restructuring by energy-based surgical tools". *Clin Plast Surg*, 2012. 39(4): p. 399-408.
- Dong, Yuan-Lin et al., "Effect of Ibuprofen on the Inflammatory Response to Surgical Wounds" *The Journal of Trauma*, vol. 35, No. 3. (1993).
- Dvivedi, Sanjay, et al. "Effect of Ibuprofen and diclofenac sodium on experimental wound healing" *Indian Journal of Experimental Biology*, vol. 35, pp. 1243-1245. (Nov. 1997).
- Fabi, S.G., "Microfocused Ultrasound With Visualization for Skin Tightening and Lifting: My Experience and a Review of the Literature". *Dermatol Surg*. Dec. 2014; 40 Suppl 12:S164-7.
- Fabi, S.G., "Noninvasive skin tightening: focus on new ultrasound techniques". *Clin Cosmet Investig Dermatol*. Feb. 5, 2015; 8:47-52.
- Fabi, S.G., et. al., "A prospective multicenter pilot study of the safety and efficacy of microfocused ultrasound with visualization for improving lines and wrinkles of the décolleté". *Dermatol Surg*. Mar. 2015; 41(3):327-35.
- Fabi, S.G., et. al., "Evaluation of microfocused ultrasound with visualization for lifting, tightening, and wrinkle reduction of the décolletage". *J Am Acad Dermatol*, 2013. 69(6): p. 965-71.
- Fabi, S.G., et. al., "Future directions in cutaneous laser surgery". *Dermatol Clin*, 2014. 32(1): p. 61-9.
- Fabi, S.G., et. al., "Retrospective Evaluation of Micro-focused Ultrasound for Lifting and Tightening the Face and Neck". *Dermatol Surg*, 2014.
- Friedmann D.P., "Comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face". *Aesthet Surg J*. Mar. 2015;35(3):NP81-2.
- Friedmann, D.P., et. al., "Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face". *J Cosmet Dermatol*, 2014. 13(2): p. 109-18.
- Fry W.J. et al., "Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound," *J. Neurosurg.*, 11:471-478; 1954.
- Fujimoto, et al., "A New Cavitation Suppression Technique for Local Ablation Using High-Intensity Focused Ultrasound" *Ultrasonics Symposium—1629* (1995).
- Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, *Arch Facial Plastic Surgery*, Mar. 1, 2007, vol. 9, No. 1.
- Gold, M.H., et. al., "Use of Micro-Focused Ultrasound with Visualization to Lift and Tighten Lax Knee Skin". *J Cosmet Laser Ther*, 2014: p. 1-15.
- Goldberg, D.J., et. al., "Safety and Efficacy of Microfocused Ultrasound to Lift, Tighten, and Smooth the Buttocks". *Dermatol Surg* 2014; 40:1113-1117.
- Greene, R.M., et al., "Skin tightening technologies". *Facial Plast Surg*. Feb. 2014; 30(1):62-7.
- Greenhalgh, David G., "Wound healing and diabetes mellitus" *Clinics in Plastic Surgery* 30; 37-45. (2003).
- Guo, S. et al., "Factors Affecting Wound Healing" *Critical Reviews in Oral Biology & Medicine*, *J Dent Res* 89(3), pp. 219-229. (2010).
- Haar, G.R. et al., "Tissue Destruction with Focused Ultrasound in Vivo," *Eur. Urol.* 23 (suppl. 1):8-11; 1993.
- Hantash, Basil M. et al., "Bipolar Fractional Radiofrequency Treatment Induces Neocollagenesis and Neocollagenesis" *Lasers in Surgery and Medicine* 41:1-9 (2009).
- Hantash, Basil M. et al., "In Vivo Histological Evaluation of a Novel Ablative Fractional Resurfacing Device" *Lasers in Surgery and Medicine* 39:96-107 (2007).
- Harris, M.O., "Safety of Microfocused Ultrasound With Visualization in Patients With Fitzpatrick Skin Phototypes III to VI". *JAMA Facial Plast. Surg*, 2015.
- Hart, et. al., "Current Concepts in the Use of PLLA: Clinical Synergy Noted with Combined Use of Microfocused Ultrasound and Poly-L-Lactic Acid on the Face, Neck, and Décolletage". *Amer. Soc. Plast. Surg.* 2015. 136; 180-187S.
- Hassan et al., "Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods," *advanced in Polymer Science*, 2000, pp. 37-65, vol. 153.
- Hassan et al., "Structure and Morphology of Freeze/Thawed PVA Hydrogels," *Macromolecules*, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.
- Hexsel et al., "A Validated Photonumeric Cellulite Severity Scale"; *J Eur Acad Dermatol Venereol*. May 2009; 23(5):523-8, 6 pages.
- Hitchcock, T.M. et al., "Review of the safety profile for microfocused ultrasound with Visualization". *Journal of Cosmetic Dermatology*, 13, 329-335. (2014).
- Hussein et al., "The Role of Cavitation in Acoustically Activated Drug Delivery," *J. Control Release*, Oct. 3, 2005, pp. 253-261, vol. 107(2).
- Hussein et al. "Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles," *BMD Cancer* 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
- Hynynen et al., Temperature Distributions During Local Ultrasound Induced Hyperthermia In Vivo, *Ultrasonics Symposium—745* (1982).
- Jeffers et al., "Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms," 1993 *IEEE Ultrasonics Symposium*, pp. 925-928.
- Jenne, J., et al., "Temperature Mapping for High Energy US-Therapy", 1994 *Ultrasonics Symposium*, pp. 1879-1882.
- Jeong, K.H., et al., "Neurologic complication associated with intense focused ultrasound". *J Cosmet Laser Ther*, 2013.

(56)

References Cited

OTHER PUBLICATIONS

- Johnson, S.A., et al., "Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography", *Ultrasonics Symposium Proceedings*, pp. 977-982. (1977).
- Kim, H.J., et al., "Coagulation and ablation patterns of high-intensity focused ultrasound on a tissue mimicking phantom and cadaveric skin". *Laser Med Sci.* Sep. 4, 2015.
- Kornstein, A.N., "Ulthera for silicone lip correction". *Plast Reconstr Surg.* 2012. 129(6): p. 1014e-1015e.
- Kornstein, A.N., "Ultherapy shrinks nasal skin after rhinoplasty following failure of conservative measures". *Plast Reconstr Surg.* 2013. 131(4): p. 664e-6e.
- Krischak, G.D., et al., "The effects of non-steroidal anti-inflammatory drug application on incisional wound healing in rats" *Journal of Wound Care*, vol. 6, No. 2, (Feb. 2007).
- Laubach, H.J., et al., "Confined Thermal Damage with Intense Ultrasound (IUS)" [abstr.] *American Society for Laser Medicine and Surgery Abstracts*, p. 15 #43 (Apr. 2006).
- Laubach, H.J., et al., "Intense focused ultrasound: evaluation of a new treatment modality for precise microcoagulation within the skin". *Dermatol Surg.* 2008. 34(5): p. 727-34.
- Lee, H.J., et al., "The efficacy and safety of intense focused ultrasound in the treatment of enlarged facial pores in Asian skin". *J Dermatolog Treat.* 2014.
- Lee H.S., et al., "Multiple Pass Ultrasound Tightening of Skin Laxity of the Lower Face and Neck". *Dermatol Surg.* 2011.
- Lin, Sung-Jan, et al., "Monitoring the thermally induced structural transitions of collagen by use of second-harmonic generation microscopy" *Optics Letters*, vol. 30, No. 6, (Mar. 15, 2005).
- Macgregor J.L., et al., "Microfocused Ultrasound for Skin Tightening". *Semin Cutan Med Surg* 32:18-25. (2013).
- Madersbacher, S. et al., "Tissue Ablation in Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound," *Dur. Urol.*, 23 (suppl. 1):39-43; 1993.
- Makin et al., "B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays," *Ultrasonics Symposium*, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
- Makin et al., "Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays," 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.
- Makin et al., "Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging," *UltraSound Med. Biol.* 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
- Manohar et al., "Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms," *Journal of Biomedical Optics*, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
- Mast et al., "Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling and Experiments," *J. Acoust. Soc. Am.*, Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
- Meshkinpour, Azin, et al., "Treatment of Hypertrophic Scars and Keloids With a Radiofrequency Device: A Study of Collagen Effects" *Lasers in Surgery and Medicine* 37:343-349 (2005).
- Minkis, K., et al., "Ultrasound skin tightening". *Dermatol Clin.* 2014. 32(1): p. 71-7.
- Mitragotri, S., "Healing sound: the use of ultrasound in drug delivery and other therapeutic applications," *Nature Reviews: Drug Delivery*, pp. 255-260, vol. 4 (Mar. 2005).
- Mosser, David M. et al., "Exploring the full spectrum of macrophage activation" *Nat Rev Immunol*; 8(12): 958-969. (Dec. 2008).
- Murota, Sei-Itsu, et al., "Stimulatory Effect of Prostaglandins on the Production of Hexosamine-Containing Substances by Cultured Fibroblasts (3) Induction of Hyaluronic Acid Synthetase by Prostaglandin" Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Nov. 1977, vol. 14, No. 5).
- Murota, Sei-Itsu, et al., "The Stimulatory Effect of Prostaglandins on Production of Hexosamine-Containing Substances by Cultured Fibroblasts" Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo-173, Japan. (Aug. 1976, vol. 12, No. 2).
- Nestor, M.S. et. al., "Safety and Efficacy of Micro-focused Ultrasound Plus Visualization for the Treatment of Axillary Hyperhidrosis". *J Clin Aesthet Dermatol.* 2014. 7(4): p. 14-21.
- Oni, G., et. al. "Response to 'comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face'". *Aesthet Surg J.* Mar. 2015;35(3):NP83-4.
- Oni, G., et. al., "Evaluation of a Microfocused Ultrasound System for Improving Skin Laxity and Tightening in the Lower Face". *Aesthet Surg J.* 2014. 38:861-868.
- Pak C.S., et. al., "Safety and Efficacy of Ulthera in the Rejuvenation of Aging Lower Eyelids: A Pivotal Clinical Trial". *Aesthetic Plast Surg.* 2014.
- Paradossi et al., "Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications," *Journal of Materials Science: Materials in Medicine*, 2003, pp. 687-691, vol. 14.
- Pritzker, R.N., et. al., "Updates in noninvasive and minimally invasive skin tightening". *Semin Cutan Med Surg.* Dec. 2014;33(4):182-7.
- Pritzker, R.N., et. al., "Comparison of different technologies for noninvasive skin tightening". *Journal of Cosmetic Dermatology*, 13, 315-323. (2014).
- Rappolee, Daniel A., et al., "Wound Macrophages Express TGF and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping" *Science*, vol. 241, No. 4866 (Aug. 1988).
- Reid, Gavin, et al., "Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions," *Analytical Chemistry*. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
- Righetti et al., "Elastographic Characterization of HIFU-Induced Lesions in Canine Livers," 1999, *Ultrasound in Med & Bio*, vol. 25, No. 7, pp. 1099-1113.
- Rokhsar, C., et. al., "Safety and efficacy of microfocused ultrasound in tightening of lax elbow skin". *Dermatol Surg.* 2015; 41(7):821-6.
- Rosenberg, Carol S. "Wound Healing in the Patient with Diabetes Mellitus" *Nursing Clinics of North America*, vol. 25, No. 1, (Mar. 1990).
- Saad et al., "Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors," *Ultrasound in Med. & Biol.* vol. 18, No. 8, pp. 715-723 (1992).
- Sabet-Peyman, E.J. et. al., "Complications Using Intense Ultrasound Therapy to Treat Deep Dermal Facial Skin and Subcutaneous Tissues". *Dermatol Surg* 2014; 40:1108-1112.
- Sandulache, Vlad C. et al., "Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)- β 1-induced collagen synthesis" *Wound Rep Reg* 15 122-133, 2007. (2007).
- Sanghvi, N.T., et al., "Transrectal Ablation of Prostate Tissue Using Focused Ultrasound," 1993 *Ultrasonics Symposium*, IEEE, pp. 1207-1210.
- Sasaki, G.H. et. al., "Clinical Efficacy and Safety of Focused-Image Ultrasonography: A 2-Year Experience". *Aesthet Surg J.* 2012.
- Sasaki, G.H. et. al., "Microfocused Ultrasound for Nonablative Skin and Subdermal Tightening to the Periorbitum and Body Sites: Preliminary Report on Eighty-Two Patients". *Journal of Cosmetics, Dermatological Sciences and Applications*, 2012, 2, 108-116.
- Sassen, Sander, "ATI's R520 architecture, the new king of the hill?" <http://www.hardwareanalysis.com/content/article/1813>, Sep. 16, 2005, 2 pages.
- Seip, Ralf, et al., "Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields," *IEEE Symposium*, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
- Seip, Ralf, et al., "Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound," *IEEE Transactions on Biomedical Engineering*, vol. 42, No. 8, Aug. 1995, pp. 828-839.
- Simon et al., "Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy," *Ultrasound in Med. & Biol.* vol. 19, No. 2, pp. 123-125 (1993).
- Sklar, L.R., et. al. "Use of transcutaneous ultrasound for lipolysis and skin tightening: a review". *Aesthetic Plast Surg.* 2014. 38(2): p. 429-41.

(56)

References Cited

OTHER PUBLICATIONS

- Smith, Nadine Barrie, et al., "Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques", 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.
- Suh, D.H. et. al., "A intense-focused ultrasound tightening for the treatment of infraorbital laxity". *J Cosmet Laser Ther*, 2012. 14(6): p. 290-5.
- Suh, D.H., et. al., "Comparative histometric analysis of the effects of high-intensity focused ultrasound and radiofrequency on skin". *J Cosmet Laser Ther*. Mar. 24, 2015:1-7.
- Suh, D.H., et. al., "Intense Focused Ultrasound Tightening in Asian Skin: Clinical and Pathologic Results" American Society for Dermatologic Surgery, Inc.; 37:1595-1602. (2011).
- Surry et al., "Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging." *Phys. Med. Biol.*, Dec. 6, 2004, pp. 5529-5546, vol. 49.
- Syka J. E. P. et al., "Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry," Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
- Talbert, D. G., "An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays," UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.
- Tata et al., "Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions," American Chemical Society, *Phys. Chem.* 1992, 96, pp. 3548-3555.
- Ueno, S., et al., "Ultrasound Thermometry in Hyperthermia", 1990 Ultrasonic Symposium, pp. 1645-1652.
- Verhofstad, Michiel H.J. et al., "Collagen Synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors" *Int. J. Exp. Path.* (1998), 79, 321-328.
- Wang, H., et al., "Limits on Focused Ultrasound for Deep Hyperthermia", 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
- Wasson, Scott, "NVIDIA's GeForce 7800 GTX graphics processor Power MADD," <http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1>, Jun. 22, 2005, 4 pages.
- Weiss, M., "Commentary: noninvasive skin tightening: ultrasound and other technologies: where are we in 2011?" *Dermatol Surg*, 2012. 38(1): p. 28-30.
- White et al "Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy," *Arch Facial Plastic Surgery*, Jan./Feb. 2007, vol. 9, No. 1 (pp. 22-29).
- White, W. M., et al., "Selective Transcutaneous Delivery of Energy to Facial Subdermal Tissues Using the Ultrasound Therapy System" [abstr]. American Society for Laser Medicine and Surgery Abstracts, p. 37 #113 (Apr. 2006).
- White, W. Matthew, et al., "Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS)" *Lasers in Surgery and Medicine* 40:67-75 (2008).
- Woodward, J.A., et. al. "Safety and Efficacy of Combining Microfocused Ultrasound With Fractional CO₂ Laser Resurfacing for Lifting and Tightening the Face and Neck". *Dermatol Surg*, Dec. 2014 40:S190-S193.
- Zelickson, Brian D. et al., "Histological and Ultrastructural Evaluation of the Effects of a Radiofrequency-Based Nonablative Dermal Remodeling Device, A Pilot Study" *Arch Dermatol*, vol. 140, (Feb. 2004).
- Ulthera, Inc., Petition for Inter Partes Review filed Jul. 19, 2016 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 63 pages (Filed Jul. 19, 2016).
- Ulthera Exhibit 1001, U.S. Pat. No. 6,113,559 to Klopotek, filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1002, Patent file history of U.S. Pat. No. 6,113,559 Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1003, Declaration of Expert Witness Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1004, Curriculum Vitae of Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1005, International PCT Publication WO96/34568 Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1006, French U.S. Pat. No. 2,672,486, Technomed patent filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1007, English translation of French Patent No. 2,672,486, Technomed filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1008, International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1009, English translation of International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1010, U.S. Pat. No. 5,601,526, which claims priority to Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1011, Patent file history for European Patent Application No. 98964890.2, Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1012, Translator Declaration filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1013, U.S. Pat. No. 5,230,334 to Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1014, U.S. Pat. No. 5,755,753 to Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1015, Excerpts from the American Medical Association Encyclopedia of Medicine (1989) filed Jul. 19, 2016 in re IPR2016-01459.
- Ulthera Exhibit 1016, The Simultaneous Study of Light Emissions and Shock Waves Produced by Cavitation Bubbles, G. Gimenez, J. Acoust. Soc. Am. 71(4), Apr. 1982, pp. 839-847 (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1017, Excerpts from Gray's Anatomy (1995) (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1018, Anatomy of the Superficial Venous System, Comjen G.M., *Dermatol. Surg.*, 1995; 21:35-45 (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1019, Section 2.6 from Ultrasonics Theory and Application, by G.L. Gooberman (Hart Publishing Co., 1969) (filed Jul. 19, 2016 in re IPR2016-01459).
- Ulthera Exhibit 1020, Deep Local Hyperthermia for Cancer Therapy: External Electromagnetic and Ultrasound Techniques, A.Y. Cheung and A. Neyzari, *Cancer Research (Suppl.)*, vol. 44, pp. 4736-4744 (1984) (filed Jul. 19, 2016 in re IPR2016-01459).
- Decision on Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 20 pages [011] (Dated Jan. 23, 2017).
- Dermafocus Response to Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 73 pages [018] (Dated Apr. 26, 2017).
- Dermafocus Exhibit List in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages [019] (Dated Apr. 26, 2017).
- Dermafocus Exhibit 2002, Declaration of Mark Palmeri, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 136 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2003, Deposition of Dr. Mark Schafer, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 327 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2004, Amendment No. 4 to Ulthera Form S-1, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 308 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2005, Excerpt from Churchill Livingstone, Gray's Anatomy (38th ed. 1995), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2006, Bo Eklof et al., "Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement," ACTA FAC MED NAISS, vol. 25, No. 1 (2008), 3-10 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2007, WebMD, "Varicose Veins and Spider Veins" downloaded from <http://www.webmd.com/skin-problems-and-treatments/guide/varicose-spider-veins#1> in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 3 pages (Filed Apr. 26, 2017).
- Dermafocus Exhibit 2008, John M. Porter et al., "Reporting Standards in Venous Disease: An Update," *Journal of Vascular Surgery*,

(56)

References Cited**OTHER PUBLICATIONS**

vol. 21, No. 4 (1995), 635-645 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2009, Kullervo Hynynen, "Review of Ultrasound Therapy," 1997 Ultrasonics Symposium (1997), 1305-1313, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2010, A.G. Visioli et al, "Preliminary Results of a Phase I Dose Escalation Clinical Trial Using Focused Ultrasound in the Treatment of Localised Tumours," European Journal of Ultrasound, vol. 9 (1999), 11-18, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 8 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2011, U.S. Pat. No. 5,143,063, issued on Sep. 1, 1992, Fellner, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2012, Hugh G. Beebe et al, "Consensus Statement: Classification and Grading of Chronic Venous Disease in the Lower Limbs," European Journal of Vascular and Endovascular Surgery, vol. 12 (1996), 487-492, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2013, Excerpt from Mosby's Medical Dictionary (3rd ed. 1990), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2014, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (5th ed. 1992), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2015, David J. Tibbs et al, Varicose Veins, Venous Disorders, and Lymphatic Problems in the Lower Limbs (1997), Chapter 4: Clinical Patterns of Venous Disorder I, 47-67, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 24 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2016, Mitchel P. Goldman et al, Varicose Veins and Telangiectasias (2nd ed. 1999), Chapter 22: Treatment of Leg Telangiectasias with Laser and High-Intensity Pulsed Light, 470-497, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 31 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2017, Email from Anderson to Klopotek dated May 25, 2004, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page (Filed Apr. 26, 2017).

Dermafocus Exhibit 2018, List of Klopotek Patents, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 411 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2019, Declaration of Peter Klopotek Civil Action 15-cv-654-SLR, dated Nov. 2, 2016, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page. (Filed Apr. 26, 2017).

Dermafocus Exhibit 2020, "Our Technology," downloaded from <http://jobs.ulthera.com/about> on Apr. 10, 2017, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2021, C. Damianou and K. Hynynen, "Focal Spacing and Near-Heating During Pulsed High Temperature Ultrasound Therapy," Ultrasound in Medicine & Biology, vol. 19, No. 9 (1993), 777-787, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2022, Excerpt from Mosby's Medical Dictionary (5th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2023, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (6th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2024, Excerpt from Stedman's Concise Medical Dictionary (3rd ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2025, Excerpt from Taber's Cyclopedic Medical Dictionary (18th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017).

Dermafocus Exhibit 2026, Bo Eklof et al, "Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement," Journal of Vascular Surgery, vol. 40, No. 6 (2004), 1248-1252.e1, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).

Ulthera, Inc., Reply in Support of Petition for Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 33 pages (Filed Aug. 2, 2017).

Ulthera Exhibit 1022, Use of the Argon and Carbon Dioxide Lasers for Treatment of Superficial Venous Varicosities of the Lower Extremity, D. Apfelberg et al., Lasers in Surgery and Medicine, vol. 4.3, pp. 221-231 (1984) (filed Aug. 2, 2017 in re IPR2016-01459).

Ulthera Exhibit 1023, 532-Nanometer Green Laser Beam Treatment of Superficial Varicosities of the Lower Extremities, T. Smith et al., Lasers in Surgery and Medicine, vol. 8.2, pp. 130-134 (1988) (filed Aug. 2, 2017 in re IPR2016-01459).

Ulthera Exhibit 1024, Deposition Transcript of Dr. Mark Palmeri on Jul. 11, 2017 (filed Aug. 2, 2017 in re IPR2016-01459).


Ulthera Exhibit 1025, Ulthera Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459).

Dermafocus Exhibit 2027, DermaFocus Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459).

PTAB Record of Oral Hearing held Oct. 4, 2017 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 67 pages (PTAB Document sent to Ulthera on Nov. 1, 2017).

Final Written Decision of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 37 pages [030] (Entered Jan. 19, 2018).

* cited by examiner

**FIG. 1**









FIG. 2


**FIG. 3A**


**FIG. 3B**

**FIG. 4A**

**FIG. 4B**

**FIG. 5**

**FIG. 6A**

**FIG. 6B**




FIG. 7




FIG. 8A







FIG. 8B

**FIG. 9**

**FIG. 10A**

**FIG. 10B**




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F





FIG. 11

**FIG. 12**

ULTRASOUND PROBE FOR FAT AND CELLULITE REDUCTION

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 15/821,281 filed Nov. 22, 2017, issued as U.S. Pat. No. 10,010,725, which is a continuation of U.S. patent application Ser. No. 15/650,246 filed Jul. 14, 2017, now U.S. Pat. No. 9,827,450, which is a continuation of U.S. patent application Ser. No. 15/374,918 filed Dec. 9, 2016, now U.S. Pat. No. 9,707,412, which is a continuation of U.S. application Ser. No. 15/041,829 filed Feb. 11, 2016, now U.S. Pat. No. 9,522,290, which is a continuation of U.S. application Ser. No. 14/550,720 filed Nov. 21, 2014, now U.S. Pat. No. 9,283,410, which is a continuation of U.S. application Ser. No. 14/164,598 filed Jan. 27, 2014, now U.S. Pat. No. 8,915,854, which is a continuation of U.S. application Ser. No. 13/789,562 filed Mar. 7, 2013, now U.S. Pat. No. 8,636,665, which is a continuation of U.S. application Ser. No. 13/356,405 filed Jan. 23, 2012, now U.S. Pat. No. 8,672,848, which is a continuation of U.S. application Ser. No. 11/163,154 filed on Oct. 6, 2005, now U.S. Pat. No. 8,133,180, which claims the benefit of priority to U.S. Provisional No. 60/616,753, filed on Oct. 6, 2004, each of which are hereby incorporated by reference in their entirety herein. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.

BACKGROUND

Field of the Invention

The present invention relates to ultrasound therapy systems, and in particular to a method and system for treating cellulite.

Description of the Related Art

Cellulite is a common skin disorder that appears as an irregularity of skin contour, often characterized by a dimple appearance of the skin. This condition affects 80% of women worldwide and tends to gather superficially around the thighs, hips, and buttocks.

Cellulite develops in the body when fat is deposited immediately below the dermis and contained in fat chambers (lobuli) that can become swollen. As the fat cells grow in size, lobuli tend to protrude into a dermis layer, surrounding tissue becomes compressed and hardened, making blood circulation more difficult in trapping fluids. Reduced elasticity of the adipose tissue produces an undesirable tension between the layers. The resulting protrusions and depressions of connective tissue anchor points create the appearance of cellulite.

This condition responds with varying results to invasive procedures, such as liposuction. The non-invasive technologies such as massagers, and low frequency ultrasound diathermy, show marginal results. Preliminary results shown by combination of infrared light and RF energy have some promise of improving skin contours, but significant progress is needed.

SUMMARY

In accordance with various aspects of the present invention, a method and system for non-invasive treatment of

cellulite with ultrasound are provided. An exemplary treatment method and system comprises a therapeutic ultrasound system for providing ultrasound treatment to a deep tissue region that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis. Such an exemplary treatment system delivers conformal ultrasound therapeutic energy to the region creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis the dermis resulting in improved appearance of the overlying superficial layers of the skin. In accordance with exemplary embodiments, an exemplary treatment system may include ultrasound imaging mechanisms using the same or a separate probe before, after or during the treatment. Other imaging configurations can be utilized to image, monitor, and provide feedback of ultrasound therapy, such as MRI, X-Ray, PET, infrared or others.

BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may best be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals:

FIG. 1 illustrates a block diagram of an exemplary ultrasound treatment system for treating cellulite in accordance with an exemplary embodiment of the present invention;

FIG. 2 illustrates a cross sectional diagram of an exemplary probe system in accordance with exemplary embodiments of the present invention;

FIGS. 3A and 3B illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention;

FIGS. 4A and 4B illustrate block diagrams of an exemplary probe system in accordance with exemplary embodiments of the present invention;

FIG. 5 illustrates a cross-sectional diagram of an exemplary transducer in accordance with an exemplary embodiment of the present invention;

FIGS. 6A and 6B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;

FIG. 7 illustrates exemplary transducer configurations for ultrasound treatment in accordance with various exemplary embodiments of the present invention;

FIGS. 8A and 8B illustrate cross-sectional diagrams of an exemplary transducer in accordance with another exemplary embodiment of the present invention;

FIG. 9 illustrates an exemplary transducer configured as a two-dimensional array for ultrasound treatment in accordance with an exemplary embodiment of the present invention;

FIGS. 10A-10F illustrate cross-sectional diagrams of exemplary transducers in accordance with other exemplary embodiments of the present invention;

FIG. 11 illustrates a schematic diagram of an acoustic coupling and cooling system in accordance with an exemplary embodiment of the present invention; and

FIG. 12 illustrates a block diagram of a treatment system comprising an ultrasound treatment subsystem combined with additional subsystems and methods of treatment monitoring and/or treatment imaging as well as a secondary

treatment subsystem in accordance with an exemplary embodiment of the present invention.

DETAILED DESCRIPTION

The present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, the present invention may be practiced in any number of medical contexts and that the exemplary embodiments relating to a non-invasive cellulite treatment system as described herein are merely indicative of exemplary applications for the invention. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of the present invention may be suitably applied to other applications.

In accordance with various aspects of the present invention, a non-invasive method and system for treating cellulite are provided. For example, in accordance with an exemplary embodiment, with reference to FIG. 1, an exemplary treatment system **100** configured to treat a region of interest **106** comprises a control system **102**, an imaging/therapy probe with acoustic coupling **104**, and a display system **108**.

Control system **102** and display system **108** can comprise various configurations for controlling probe **104** and overall system **100** functionality, such as, for example, a microprocessor with software and a plurality of input/output devices, system and devices for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers, and/or systems for handling user input and recording treatment results, among others. Imaging/therapy probe **104** can comprise various probe and/or transducer configurations. For example, probe **104** can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, or simply a separate therapy probe and an imaging probe.

In accordance with an exemplary embodiment, treatment system **100** is configured for treating a deep tissue region that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis, by first, imaging of region of interest **106** for localization of the treatment area and surrounding structures, second, delivery of ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect, and third to monitor the treatment area before, during, and after therapy to plan and assess the results and/or provide feedback. As to the delivery of energy, control system **102** and transducer system **102** can be suitably configured to deliver conformal ultrasound therapeutic energy to ROI **106** creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. As used herein, the term "dermis" refers to any part of the dermis and/or the epidermis.

In addition, by treatment of ROI **106**, transducer system **102** may be configured to deliver one or more energy fields to promote one or more effects, for example, ablation of existing tissue, the breaking up of fat cell clusters, stretching of the fibrous bonds, enhancement of lymphatic drainage,

stimulation of the evacuation of fat decay products, and/or enhanced cell permeability in order to treat cellulite.

An exemplary ultrasound therapy system of FIG. 1 is further illustrated in an exemplary embodiment in FIG. 2. A therapy transducer system **200** includes a transducer probe **202** connected to a control system **204**, and display **206**, in combination may provide therapy, imaging, and/or temperature or other tissue parameters monitoring to region of interest **210**. Exemplary transducer system **200** is configured for first, imaging and display of region of interest **210** for localization of the treatment area and surrounding structures, second, delivery of focused, unfocused, or defocused ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect of thermal ablation to treat cellulite, and third to monitor the treatment area and surrounding structures before, during, and after therapy to plan and assess the results and/or provide feedback to control system **204** and/or an operator.

Exemplary transducer probe **202** can be configured to be suitably controlled and/or operated in various manners. For example, transducer probe **202** may be configured for use within an ultrasound treatment system, an ultrasound imaging system and/or an ultrasound imaging, therapy, and/or treatment monitoring system, including motion control subsystems.

Control system **204** can be configured with one or more subsystems, processors, input devices, displays and/or the like. Display **206** may be configured to image and/or monitor ROI **210** and/or any particular sub-region within ROI **210**. Display **206** can be configured for two-dimensional, three-dimensional, real-time, analog, digital and/or any other type of imaging. Exemplary embodiments of both control system **204** and display **206** are described in greater detail herein.

Region of interest **210**, can be comprised of superficial layer (epidermis/dermis) subcutaneous fat, lobuli, and muscle. Exemplary transducer system **200**, is configured to provide cross-sectional two-dimensional imaging of the region **207**, displayed as an image **205**, with a controlled thermal lesion **209**, confined approximately to proximal portion of fat lobuli and lower portion of dermis.

Transducer system **200** can be configured with the ability to controllably produce conformal treatment areas in superficial human tissue within region of interest **210** through precise spatial and temporal control of acoustic energy deposition. In accordance with an exemplary embodiment, control system **204** and transducer probe **202** can be suitably configured for spatial control of the acoustic energy by controlling the manner of distribution of the acoustical energy. For example, spatial control may be realized through selection of the type of one or more transducer configurations insonifying region of interest **210**, selection of the placement and location of transducer probe **202** for delivery of acoustical energy relative to region-of-interest **210**, e.g., transducer probe **202** configured for scanning over part or whole of region-of-interest **210** to deliver conformal ultrasound therapeutic energy to create a thermal injury and to coagulate the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. Transducer probe **202** may also be configured for control of other environment parameters, e.g., the temperature at the acoustic coupling interface can be controlled. In addition to the spatial control, control system **204** and/or transducer probe **202** can also be configured for temporal control, such as through adjustment and optimization of drive amplitude levels, frequency/waveform selections, and timing sequences and other energy drive characteristics to control

the treatment of tissue. The spatial and/or temporal control can also be facilitated through open-loop and closed-loop feedback arrangements, such as through the monitoring of various positional and temporal characteristics. For example, through such spatial and/or temporal control, an exemplary treatment system **200** can enable the regions of thermal injury to possess arbitrary shape and size and allow the tissue to be treated in a controlled manner.

Transducer system **200** may be used to provide a mechanical action of ultrasound to physically break fat cell clusters and stretch the fibrous bonds. This mechanical action will also enhance lymphatic drainage, stimulating the evacuation of fat decay products. That is, the ultrasound may facilitate movement of the muscles and soft tissues within ROI **210**, thereby facilitating the loosening of fat deposits and/or the break up of fibrous tissue surrounding fat deposits.

In addition, transducer system **200** can be configured to deliver various therapeutic levels of ultrasound to increase the speed at which fat metabolizes, according to the Arrhenius Law: $Y=Ae^{-B/T}$, where Y is the yield of metabolic reaction, A and B are constants, and T is the temperature in degrees Kelvin. In one exemplary embodiment, transducer system **200** is configured to provide various therapeutic levels of ultrasound to increase the speed at which fat metabolizes. That is, according to Arrhenius Law, the yield, Y of a metabolic reaction is a function of temperature, T: $Y=Ae^{-B/T}$, where A and B are constants, and T is the temperature in degrees Kelvin. Thus, ultrasound treatment from transducer system **200**, ranging from approximately 750 kHz to 20 MHz, can increase the temperature in a treatment area, thereby increasing the metabolic reaction yield for that treatment area.

As previously described, control systems **104** and **204** may be configured in various manners with various subsystems and subcomponents. With reference to FIGS. 3A and 3B, in accordance with exemplary embodiments, an exemplary control system **300** can be configured for coordination and control of the entire therapeutic treatment process in accordance with the adjustable settings made by a therapeutic treatment system user. For example, control system **300** can suitably comprise power source components **302**, sensing and monitoring components **304**, cooling and coupling controls **306**, and/or processing and control logic components **308**. Control system **300** can be configured and optimized in a variety of ways with more or less subsystems and components to implement the therapeutic system for cellulite treatment, and the embodiment in FIGS. 3A and 3B are merely for illustration purposes.

For example, for power sourcing components **302**, control system **300** can comprise one or more direct current (DC) power supplies **303** configured to provide electrical energy for entire control system **300**, including power required by a transducer electronic amplifier/driver **312**. A DC current sense device **305** can also be provided to confirm the level of power going into amplifiers/drivers **312** for safety and monitoring purposes.

Amplifiers/drivers **312** can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, amplifiers/drivers **312** can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer **310** with related switching logic.

The power sourcing components can also include various filtering configurations **314**. For example, switchable har-

monic filters and/or matching may be used at the output of amplifier/driver **312** to increase the drive efficiency and effectiveness. Power detection components **316** may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components **316** may be used to monitor the amount of power going to an exemplary probe system.

Various sensing and monitoring components **304** may also be suitably implemented within control system **300**. For example, in accordance with an exemplary embodiment, monitoring, sensing and interface control components **324** may be configured to operate with various motion detection systems **322** implemented within transducer probe **104** to receive and process information such as acoustic or other spatial and temporal information from a region of interest. Sensing and monitoring components can also include various controls, interfacing and switches **309** and/or power detectors **316**. Such sensing and monitoring components **304** can facilitate open-loop and/or closed-loop feedback systems within treatment system **100**.

For example, In such an open-loop system, a system user can suitably monitor the imaging and/or other spatial or temporal parameters and then adjust or modify same to accomplish a particular treatment objective. Instead of, or in combination with open-loop feedback configurations, an exemplary treatment system can comprise a closed-loop feedback system, wherein images and/or spatial/temporal parameters can be suitably monitored within monitoring component to generate signals.

During operation of exemplary treatment system **100**, a lesion configuration of a selected size, shape, orientation is determined. Based on that lesion configuration, one or more spatial parameters are selected, along with suitable temporal parameters, the combination of which yields the desired conformal lesion. Operation of the transducer can then be initiated to provide the conformal lesion or lesions. Open and/or closed-loop feedback systems can also be implemented to monitor the spatial and/or temporal characteristics, and/or other tissue parameter monitoring, to further control the conformal lesions.

Cooling/coupling control systems **306** may be provided to remove waste heat from exemplary probe **104**, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from transducer probe **104** to region-of-interest **106**. Such cooling/coupling control systems **306** can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.

Processing and control logic components **308** can comprise various system processors and digital control logic **307**, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays (FPGAs), computer boards, and associated components, including firmware and control software **326**, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software and firmware **326** controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches **308** can also be suitably configured to control operation.

An exemplary transducer probe **104** can also be configured in various manners and comprise a number of reusable and/or disposable components and parts in various embodiments to facilitate its operation. For example, transducer

probe **104** can be configured within any type of transducer probe housing or arrangement for facilitating the coupling of transducer to a tissue interface, with such housing comprising various shapes, contours and configurations depending on the particular treatment application. For example, in accordance with an exemplary embodiment, transducer probe **104** can be depressed against a tissue interface whereby blood perfusion is partially or wholly cut-off, and tissue flattened in superficial treatment region-of-interest **106**. Transducer probe **104** can comprise any type of matching, such as for example, electric matching, which may be electrically switchable; multiplexer circuits and/or aperture/element selection circuits; and/or probe identification devices, to certify probe handle, electric matching, transducer usage history and calibration, such as one or more serial EEPROM (memories). Transducer probe **104** may also comprise cables and connectors; motion mechanisms, motion sensors and encoders; thermal monitoring sensors; and/or user control and status related switches, and indicators such as LEDs. For example, a motion mechanism in probe **104** may be used to controllably create multiple lesions, or sensing of probe motion itself may be used to controllably create multiple lesions and/or stop creation of lesions, e.g. for safety reasons if probe **104** is suddenly jerked or is dropped. In addition, an external motion encoder arm may be used to hold the probe during use, whereby the spatial position and attitude of probe **104** is sent to the control system to help controllably create lesions. Furthermore, other sensing functionality such as profilometers or other imaging modalities may be integrated into the probe in accordance with various exemplary embodiments.

With reference to FIGS. **4A** and **4B**, in accordance with an exemplary embodiment, a transducer probe **400** can comprise a control interface **402**, a transducer **404**, coupling components **406**, and monitoring/sensing components **408**, and/or motion mechanism **410**. However, transducer probe **400** can be configured and optimized in a variety of ways with more or less parts and components to provide ultrasound energy for cellulite treatment, and the embodiment in FIGS. **4A** and **4B** are merely for illustration purposes.

In accordance with an exemplary embodiment of the present invention, transducer probe **400** is configured to deliver energy over varying temporal and/or spatial distributions in order to provide energy effects and initiate responses in a region of interest. These effects can include, for example, thermal, cavitation, hydrodynamic, and resonance induced tissue effects. For example, exemplary transducer probe **400** can be operated under one or more frequency ranges to provide two or more energy effects and initiate one or more responses in the region of interest. In addition, transducer probe **400** can also be configured to deliver planar, defocused and/or focused energy to a region of interest to provide two or more energy effects and to initiate one or more reactions. These responses can include, for example, diathermy, hemostasis, revascularization, angiogenesis, growth of interconnective tissue, tissue reformation, ablation of existing tissue, protein synthesis and/or enhanced cell permeability. These and various other exemplary embodiments for such combined ultrasound treatment, effects and responses are more fully set forth in U.S. patent application Ser. No. 10/950,112, entitled "METHOD AND SYSTEM FOR COMBINED ULTRASOUND TREATMENT," Filed Sep. 24, 2004 and incorporated herein by reference.

Control interface **402** is configured for interfacing **428** with control system **300** to facilitate control of transducer probe **400**. Control interface components **402** can comprise

multiplexer/aperture select **424**, switchable electric matching networks **426**, serial EEPROMs and/or other processing components and matching and probe usage information **430** and interface connectors **432**.

Coupling components **406** can comprise various devices to facilitate coupling of transducer probe **400** to a region of interest. For example, coupling components **406** can comprise cooling and acoustic coupling system **420** configured for acoustic coupling of ultrasound energy and signals. Acoustic cooling/coupling system **420** with possible connections such as manifolds may be utilized to couple sound into the region-of-interest, control temperature at the interface and deeper into tissue, provide liquid-filled lens focusing, and/or to remove transducer waste heat. Coupling system **420** may facilitate such coupling through use of various coupling mediums, including air and other gases, water and other fluids, gels, solids, and/or any combination thereof, or any other medium that allows for signals to be transmitted between transducer active elements **412** and a region of interest. In addition to providing a coupling function, in accordance with an exemplary embodiment, coupling system **420** can also be configured for providing temperature control during the treatment application. For example, coupling system **420** can be configured for controlled cooling of an interface surface or region between transducer probe **400** and a region of interest and beyond and beyond by suitably controlling the temperature of the coupling medium. The suitable temperature for such coupling medium can be achieved in various manners, and utilize various feedback systems, such as thermocouples, thermistors or any other device or system configured for temperature measurement of a coupling medium. Such controlled cooling can be configured to further facilitate spatial and/or thermal energy control of transducer probe **400**.

In accordance with an exemplary embodiment, with additional reference to FIG. **11**, acoustic coupling and cooling **1140** can be provided to acoustically couple energy and imaging signals from transducer **1104** to and from the region of interest **1102**, to provide thermal control at the probe **1100** to region-of-interest interface **1110**, and to remove potential waste heat from the transducer probe at region **1144**. Temperature monitoring can be provided at the coupling interface via a thermal sensor **1146** to provide a mechanism of temperature measurement **1148** and control via control system **1106** and a thermal control system **1142**. Thermal control may consist of passive cooling such as via heat sinks or natural conduction and convection or via active cooling such as with peltier thermoelectric coolers, refrigerants, or fluid-based systems comprised of pump, fluid reservoir, bubble detection, flow sensor, flow channels/tubing **1144** and thermal control **1142**.

Monitoring and sensing components **408** can comprise various motion and/or position sensors **416**, temperature monitoring sensors **418**, user control and feedback switches **414** and other like components for facilitating control by control system **300**, e.g., to facilitate spatial and/or temporal control through open-loop and closed-loop feedback arrangements that monitor various spatial and temporal characteristics.

Motion mechanism **410** can comprise manual operation, mechanical arrangements, or some combination thereof. For example, a motion mechanism **422** can be suitably controlled by control system **300**, such as through the use of accelerometers, encoders or other position/orientation devices **416** to determine and enable movement and positions of transducer probe **400**. Linear, rotational or variable

movement can be facilitated, e.g., those depending on the treatment application and tissue contour surface.

Transducer **404** can comprise one or more transducers configured for producing conformal lesions of thermal injury in superficial human tissue within a region of interest through precise spatial and temporal control of acoustic energy deposition. Transducer **404** can also comprise one or more transduction elements and/or lenses **412**. The transduction elements can comprise a piezoelectrically active material, such as lead zirconate titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, transducer **404** can comprise any other materials configured for generating radiation and/or acoustical energy. Transducer **404** can also comprise one or more matching layers configured along with the transduction element such as coupled to the piezoelectrically active material. Acoustic matching layers and/or damping may be employed as necessary to achieve the desired electroacoustic response.

In accordance with an exemplary embodiment, the thickness of the transduction element of transducer **404** can be configured to be uniform. That is, a transduction element **412** can be configured to have a thickness that is substantially the same throughout. In accordance with another exemplary embodiment, the thickness of a transduction element **412** can also be configured to be variable. For example, transduction element(s) **412** of transducer **404** can be configured to have a first thickness selected to provide a center operating frequency of a lower range, for example from approximately 750 kHz to 5 MHz. Transduction element **404** can also be configured with a second thickness selected to provide a center operating frequency of a higher range, for example from approximately 5 MHz to 20 MHz or more. Transducer **404** can be configured as a single broadband transducer excited with at least two or more frequencies to provide an adequate output for generating a desired response. Transducer **404** can also be configured as two or more individual transducers, wherein each transducer comprises one or more transduction element. The thickness of the transduction elements can be configured to provide center-operating frequencies in a desired treatment range. For example, transducer **404** can comprise a first transducer configured with a first transduction element having a thickness corresponding to a center frequency range of approximately 750 kHz to 5 MHz, and a second transducer configured with a second transduction element having a thickness corresponding to a center frequency of approximately 5 MHz to 20 MHz or more.

Transducer **404** may be composed of one or more individual transducers in any combination of focused, planar, or unfocused single-element, multi-element, or array transducers, including 1-D, 2-D, and annular arrays; linear, curvilinear, sector, or spherical arrays; spherically, cylindrically, and/or electronically focused, defocused, and/or lensed sources. For example, with reference to an exemplary embodiment depicted in FIG. 5, transducer **500** can be configured as an acoustic array to facilitate phase focusing. That is, transducer **500** can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays. By the term “operated,” the electronic apertures of transducer **500** may be manipulated, driven, used, and/or configured to produce and/or deliver an energy beam corresponding to the phase variation caused by the electronic time delay. For example,

these phase variations can be used to deliver defocused beams **508**, planar beams **504**, and/or focused beams **506**, each of which may be used in combination to achieve different physiological effects in a region of interest **510**. Transducer **500** may additionally comprise any software and/or other hardware for generating, producing and/or driving a phased aperture array with one or more electronic time delays.

Transducer **500** can also be configured to provide focused treatment to one or more regions of interest using various frequencies. In order to provide focused treatment, transducer **500** can be configured with one or more variable depth devices to facilitate treatment. For example, transducer **500** may be configured with variable depth devices disclosed in U.S. patent application Ser. No. 10/944,500, entitled “System and Method for Variable Depth Ultrasound”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and incorporated herein by reference. In addition, transducer **500** can also be configured to treat one or more additional ROI **510** through the enabling of sub-harmonics or pulse-echo imaging, as disclosed in U.S. patent application Ser. No. 10/944,499, entitled “Method and System for Ultrasound Treatment with a Multi-directional Transducer”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and also incorporated herein by reference.

Moreover, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the sound field. For example, with reference to exemplary embodiments depicted in FIGS. 6A and 6B, transducer **600** may also be configured with an electronic focusing array **604** in combination with one or more transduction elements **606** to facilitate increased flexibility in treating ROI **610**. Array **602** may be configured in a manner similar to transducer **502**. That is, array **602** can be configured as an array **604** of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, $T_1, T_2 \dots T_j$. By the term “operated,” the electronic apertures of array **604** may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI **610**.

Transduction elements **606** may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. 6A, transduction elements **606** are configured to be concave in order to provide focused energy for treatment of ROI **610**. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled “Variable Depth Transducer System and Method”, and again incorporated herein by reference.

In another exemplary embodiment, depicted in FIG. 6B, transduction elements **606** can be configured to be substantially flat in order to provide substantially uniform energy to ROI **610**. While FIGS. 6A and 6B depict exemplary embodiments with transduction elements **604** configured as concave and substantially flat, respectively, transduction elements **604** can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements **604** can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first

transduction element can be configured to be concave, while a second transduction element can be configured to be substantially flat.

With reference to FIGS. 8A and 8B, transducer 800 can be configured as single-element arrays, wherein a single-element 802, e.g., a transduction element of various structures and materials, can be configured with a plurality of masks 804, such masks comprising ceramic, metal or any other material or structure for masking or altering energy distribution from element 802, creating an array of energy distributions 808. Masks 804 can be coupled directly to element 802 or separated by a standoff 806, such as any suitably solid or liquid material.

An exemplary transducer 404 can also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, with reference to FIGS. 10A and 10B, in accordance with an exemplary embodiment, an annular array 1000 can comprise a plurality of rings 1012, 1014, 1016 to N. Rings 1012, 1014, 1016 to N can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, $\tau_1, \tau_2, \tau_3 \dots \tau_N$. An electronic focus can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or concave shaped annular array 1000 can also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of annular array 1000 in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within a region of interest.

Transducer 404 can also be configured in other annular or non-array configurations for imaging/therapy functions. For example, with reference to FIGS. 10C-10F, a transducer can comprise an imaging element 1012 configured with therapy element(s) 1014. Elements 1012 and 1014 can comprise a single-transduction element, e.g., a combined imaging/transducer element, or separate elements, can be electrically isolated 1022 within the same transduction element or between separate imaging and therapy elements, and/or can comprise standoff 1024 or other matching layers, or any combination thereof. For example, with particular reference to FIG. 10F, a transducer can comprise an imaging element 1012 having a surface 1028 configured for focusing, defocusing or planar energy distribution, with therapy elements 1014 including a stepped-configuration lens configured for focusing, defocusing, or planar energy distribution.

In accordance with another aspect of the invention, transducer probe 400 may be configured to provide one, two or three-dimensional treatment applications for focusing acoustic energy to one or more regions of interest. For example, as discussed above, transducer probe 400 can be suitably diced to form a one-dimensional array, e.g., a transducer comprising a single array of sub-transduction elements.

In accordance with another exemplary embodiment, transducer probe 400 may be suitably diced in two-dimensions to form a two-dimensional array. For example, with reference to FIG. 9, an exemplary two-dimensional array 900 can be suitably diced into a plurality of two-dimensional portions 902. Two-dimensional portions 902 can be suitably configured to focus on the treatment region at a certain

depth, and thus provide respective slices 904 of the treatment region. As a result, the two-dimensional array 900 can provide a two-dimensional slicing of the image plane of a treatment region, thus providing two-dimensional treatment.

In accordance with another exemplary embodiment, transducer probe 400 may be suitably configured to provide three-dimensional treatment. For example, to provide three dimensional treatment of a region of interest, with reference again to FIG. 3, a three-dimensional system can comprise transducer probe 400 configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as control system 300. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature and/or treatment information relating to the region of interest, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.

In accordance with an exemplary embodiment, with reference again to FIG. 9, an exemplary three-dimensional system can comprise a two-dimensional array 900 configured with an adaptive algorithm to suitably receive slices 904, 907 from different image planes of the treatment region, process the received information, and then provide volumetric information 906, e.g., three-dimensional imaging, temperature and/or treatment information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array 900 may suitably provide therapeutic heating to the volumetric region 906 as desired.

Alternatively, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging and/or temperature information, an exemplary three-dimensional system can comprise a single transducer 404 configured within a probe arrangement to operate from various rotational and/or translational positions relative to a target region.

To further illustrate the various structures for transducer 404, with reference to FIG. 7, ultrasound therapy transducer 700 can be configured for a single focus, an array of foci, a locus of foci, a line focus, and/or diffraction patterns. Transducer 700 can also comprise single elements, multiple elements, annular arrays, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, and mechanical and/or electronic focusing. Transducers configured as spherically focused single elements 702, annular arrays 704, annular arrays with damped regions 706, line focused single elements 708, 1-D linear arrays 710, 1-D curvilinear arrays 712 in concave or convex form, with or without elevation focusing, 2-D arrays 714, and 3-D spatial arrangements of transducers may be used to perform therapy and/or imaging and acoustic monitoring functions. For any transducer configuration, focusing and/or defocusing may be in one plane or two planes via mechanical focus 720, convex lens 722, concave lens 724, compound or multiple lenses 726, planar form 728, or stepped form, such as illustrated in FIG. 10F. Any transducer or combination of transducers may be utilized for treatment. For example, an annular transducer may be used with an outer portion dedicated to therapy and the inner disk dedicated to broadband imaging wherein such imaging transducer and therapy transducer have different acoustic lenses and design, such as illustrated in FIG. 10C-10F.

Various shaped treatment lesions can be produced using the various acoustic lenses and designs in FIGS. 10A-10F. For example, mushroom shaped lesions may be produced from a spherically focused source, and/or planar lesions

from a flat source. That is, as the application of ablative ultrasound energy continues, this causes thermal expansion to generate a growing lesion. Concave planar sources and arrays can produce a “V-shaped” or ellipsoidal lesion. Electronic arrays, such as a linear array, can produce defocused, planar, or focused acoustic beams that may be employed to form a wide variety of additional lesion shapes at various depths. An array may be employed alone or in conjunction with one or more planar or focused transducers. Such transducers and arrays in combination produce a very wide range of acoustic fields and their associated benefits. A fixed focus and/or variable focus lens or lenses may be used to further increase treatment flexibility. A convex-shaped lens, with acoustic velocity less than that of superficial tissue, may be utilized, such as a liquid-filled lens, gel-filled or solid gel lens, rubber or composite lens, with adequate power handling capacity; or a concave-shaped, low profile, lens may be utilized and composed of any material or composite with velocity greater than that of tissue. While the structure of transducer source and configuration can facilitate a particular shaped lesion as suggested above, such structures are not limited to those particular shapes as the other spatial parameters, as well as the temporal parameters, can facilitate additional shapes within any transducer structure and source.

Through operation of ultrasound system **100**, a method for treatment of cellulite can be realized that can facilitate effective and efficient therapy without creating chronic injury to human tissue. For example, a user may first select one or more transducer probe configurations for treating a region of interest. The user may select any probe configuration described herein. Because the treatment region ranges from approximately 0 mm to 3.5 cm, exemplary transducer probes may include, for example, an annular array, a variable depth transducer, a mechanically moveable transducer, a cylindrical-shaped transducer, a linear or flat transducer and the like. As used herein, the term user may include a person, employee, doctor, nurse, and/or technician, utilizing any hardware and/or software of other control systems.

Once one or more transducers are selected, the user may then image a region of interest in order to plan a treatment protocol. By imaging a region of interest, the user may use the same treatment transducer probe and/or one or more additional transducers to image the region of interest at a high resolution. In one embodiment, the transducer may be configured to facilitate high speed imaging over a large region of interest to enable accurate imaging over a large region of interest. In another embodiment, ultrasound imaging may include the use of Doppler flow monitoring and/or color flow monitoring. In addition other means of imaging such as photography and other visual optical methods, MRI, X-Ray, PET, infrared or others can be utilized separately or in combination for imaging and feedback of the superficial tissue and the vascular tissue in the region of interest.

In accordance with another exemplary embodiment, with reference to FIG. 12, an exemplary treatment system **200** can be configured with and/or combined with various auxiliary systems to provide additional functions. For example, an exemplary treatment system **1200** for treating a region of interest **1206** can comprise a control system **1202**, a probe **1204**, and a display **1208**. Treatment system **1200** further comprises an auxiliary imaging modality **1274** and/or auxiliary monitoring modality **1272** may be based upon at least one of photography and other visual optical methods, magnetic resonance imaging (MRI), computed tomography (CT), optical coherence tomography (OCT), electromagnetic, microwave, or radio frequency (RF) methods, positron

emission tomography (PET), infrared, ultrasound, acoustic, or any other suitable method of visualization, localization, or monitoring of cellulite within region-of-interest **1206**, including imaging/monitoring enhancements. Such imaging/monitoring enhancement for ultrasound imaging via probe **1204** and control system **1202** could comprise M-mode, persistence, filtering, color, Doppler, and harmonic imaging among others; furthermore an ultrasound treatment system **1270**, as a primary source of treatment, may be combined with a secondary source of treatment **1276**, including radio frequency (RF), intense pulsed light (IPL), laser, infrared laser, microwave, or any other suitable energy source.

Because the location and thickness of the fat lobuli varies from one patient to another (due to genetics, weight, age, etc.), imaging using a transducer can facilitate treatment within a patient, however imaging is not required to treat cellulite.

By planning a treatment protocol, the user may choose one or more spatial and/or temporal characteristics to provide conformal ultrasound energy to a region of interest. For example, the user may select one or more spatial characteristics to control, including, for example, the use one or more transducers, one or more mechanical and/or electronic focusing mechanisms, one or more transduction elements, one or more placement locations of the transducer relative to the region of interest, one or more feedback systems, one or more mechanical arms, one or more orientations of the transducer, one or more temperatures of treatment, one or more coupling mechanisms and/or the like.

In addition, the user may choose one or more temporal characteristics to control in order to facilitate treatment of the region of interest. For example, the user may select and/or vary the treatment time, frequency, power, energy, amplitude and/or the like in order to facilitate temporal control. For more information on selecting and controlling ultrasound spatial and temporal characteristics, see U.S. application Ser. No. 11/163,148, entitled “Method and System for Controlled Thermal Injury,” filed Oct. 6, 2005 and previously incorporated herein by reference.

After planning of a treatment protocol is complete, the treatment protocol can be implemented. That is, a transducer system can be used to deliver ultrasound energy to a treatment region to ablate select tissue in order to facilitate cellulite treatment. By delivering energy, the transducer may be driven at a select frequency, a phased array may be driven with certain temporal and/or spatial distributions, a transducer may be configured with one or more transduction elements to provide focused, defocused and/or planar energy, and/or the transducer may be configured and/or driven in any other ways hereinafter devised.

In one exemplary embodiment, energy is delivered in relatively small ablative areas in order to minimize and/or prevent scar tissue from forming. That is, each ablative area of treatment can range from approximately 100 microns to 55 mm in diameter. In another exemplary embodiment, ultrasound energy is used in a “lawnmower” type fashion to evenly ablate a treatment region to provide a substantially planar surface of lobuli. This “lawnmower”-type ablation in turn, helps to achieve a substantially smooth surface of the epidermis.

In one exemplary embodiment, energy is delivered at a treatment depth of approximately 0 mm to 3.5 cm. The energy may range from 750 kHz to about 10 MHz, with typical applications ranging from 2 MHz to 10 MHz. In order to deliver energy in this treatment range, the transducer can be driven at power levels ranging from 20 W to

200 W. Because treatment time and treatment power are interrelated, these variables may differ from one patient to another and/or from one region of interest to another.

Once the treatment protocol has been implemented, the region of tissue may have one or more reactions to the treatment. For example, in one embodiment, the tissue responds by enhancement of lymphatic drainage, evacuation of fat decay products, creation of a thermal injury and/or coagulation of proximal protrusions of fat lobuli.

Upon treatment, the steps outlined above can be repeated one or more additional times to provide for optimal treatment results. Different ablation sizes and shapes may affect the recovery time and time between treatments. For example, in general, the larger the surface area of the treatment lesion, the faster the recovery. The series of treatments can also enable the user to tailor additional treatments in response to a patient's responses to the ultrasound treatment.

The present invention has been described above with reference to various exemplary embodiments. However, those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, e.g., various steps may be deleted, modified, or combined with other steps. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

What is claimed is:

1. An ultrasound treatment probe for treatment of cellulite, the probe comprising:

a piezoelectric ultrasound therapy element connected to a motion mechanism,

wherein the piezoelectric ultrasound therapy element is configured for acoustic coupling to a skin surface,

wherein the piezoelectric ultrasound therapy element is configured for delivery of ultrasound energy at a temperature sufficient to coagulate fat cells in fat lobuli that protrude into a dermis layer to create an appearance of cellulite at a depth under the skin surface,

wherein the motion mechanism is configured to operate with an encoder configured to determine movement of the piezoelectric ultrasound therapy element within the probe,

wherein the motion mechanism moves the piezoelectric ultrasound therapy element to form one or more thermal foci at the depth for coagulating fat thereby reducing an appearance of cellulite.

2. The probe of claim 1,

wherein the encoder is configured for monitoring a position of the piezoelectric ultrasound therapy element on the motion mechanism in a housing of the ultrasound probe,

wherein the piezoelectric ultrasound therapy element is a single element that delivers the ultrasound energy at a frequency of between 2 MHz to 10 MHz,

wherein the ultrasound energy is delivered with a treatment power of between 20 W and 200 W,

wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy at the depth below the skin surface,

wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in the region of interest.

3. The probe of claim 1, wherein the piezoelectric ultrasound therapy element is one of the group consisting of spherically focused and cylindrically focused.

4. The probe of claim 1, wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y = A \cdot e^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

5. The probe of claim 1, wherein the piezoelectric ultrasound therapy element is configured to operate with a control system comprising a processor, wherein the piezoelectric ultrasound therapy element is configured for communication with the control system, wherein the probe is disposable.

6. The probe of claim 1, wherein the motion mechanism is a linear motion mechanism for linear movement of the piezoelectric ultrasound therapy element to form a plurality of thermal lesions along a line at the depth in the region of interest.

7. The probe of claim 1, further comprising a piezoelectric ultrasound imaging element and an information storage EEPROM, wherein the probe is reusable.

8. The probe of claim 1, further comprising a piezoelectric ultrasound imaging element co-housed with the piezoelectric ultrasound therapy element.

9. The probe of claim 1, wherein the motion mechanism is configured for any one of the group consisting of linear, rotational, and variable movement of the piezoelectric ultrasound therapy element.

10. An ultrasound probe for treatment of cellulite, the probe comprising:

a piezoelectric ultrasound therapy element configured for acoustic coupling through the ultrasound probe to a skin surface,

wherein a plurality of fat lobuli containing fat cells protrude into a dermis layer under the skin surface, wherein the piezoelectric ultrasound therapy element is configured for delivery of energy at a temperature sufficient to coagulate at least a portion of the fat cells in the plurality of fat lobuli at a depth under the skin surface, thereby reducing an appearance of cellulite.

11. The probe of claim 10,

wherein the piezoelectric ultrasound therapy element is a single element that delivers ultrasound energy at a frequency of between 2 MHz to 10 MHz,

wherein the ultrasound energy is delivered with a treatment power of between 20 W and 200 W,

wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy up to 3.5 cm below the skin surface,

wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in the region of interest.

12. The probe of claim 10,

further comprising a housing, the housing containing a piezoelectric ultrasound imaging element,

wherein the piezoelectric ultrasound imaging element is configured for imaging a region of interest under the skin surface, wherein the region of interest comprises a tissue, wherein the tissue comprises the plurality of fat lobuli,

wherein the probe is disposable.

17

13. The probe of claim 10,

wherein the piezoelectric ultrasound therapy element is a single element that delivers ultrasound energy at a frequency of between 750 kHz to 10 MHz, and

wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y=Ae^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

14. The probe of claim 10, further comprising a storage system comprising probe identification and probe usage history,

wherein the piezoelectric ultrasound therapy element is configured for connection to a control system,

wherein the control system comprises: a processor, software, a power supply, and a communication device.

15. An ultrasound probe for treatment of cellulite, the probe comprising:

a housing, a piezoelectric ultrasound therapy element, and a motion mechanism,

wherein the piezoelectric ultrasound therapy element delivers ultrasound energy to a tissue below a skin surface at a frequency of between 2 MHz to 10 MHz,

wherein the tissue comprises a plurality of fat lobuli that protrude into a dermis layer to create an appearance of cellulite,

wherein the piezoelectric ultrasound therapy element is configured for delivery of the ultrasound energy at a temperature sufficient to coagulate at least a portion of a plurality of fat lobuli at a depth under the skin surface,

wherein the piezoelectric ultrasound therapy element is connected to the motion mechanism inside the housing,

wherein the motion mechanism is configured to operate with an encoder,

18

wherein the motion mechanism moves the piezoelectric ultrasound therapy element to form a plurality of thermal lesions at the depth for reducing an appearance of cellulite.

16. The probe of claim 15,

wherein the piezoelectric ultrasound therapy element is a single element,

wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy at the depth below the skin surface, wherein the depth is a single, fixed depth,

wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in a region of interest.

17. The probe of claim 15, wherein the piezoelectric ultrasound therapy element is configured to operate with a control system that comprises a spatial control and a temporal control, the spatial control and the temporal control controlling the delivery of the ultrasound energy at a temperature sufficient to cause coagulation of at least the portion of the plurality of fat lobuli at the depth under the skin surface, wherein the ultrasound energy is delivered with a treatment power of between 20 W and 200 W.

18. The probe of claim 17, further comprising a storage system comprising probe identification and probe usage history, wherein the probe is disposable.

19. The probe of claim 15, wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: $Y=A \cdot e^{-B/T}$, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.

20. The probe of claim 15, wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy at an energy level for causing at least one of ablating tissue, stretching fibrous bonds, or stimulating evacuation of fat decay products in the region of interest.

* * * * *

| | | | |
|---------------|--|---------|------------|
| 专利名称(译) | 用于减少脂肪和脂肪团的超声波探头 | | |
| 公开(公告)号 | US10245450 | 公开(公告)日 | 2019-04-02 |
| 申请号 | US15/996295 | 申请日 | 2018-06-01 |
| 申请(专利权)人(译) | 引导治疗系统公司 | | |
| 当前申请(专利权)人(译) | 引导治疗系统公司 | | |
| [标]发明人 | SLAYTON MICHAEL H BARTHE PETER G MAKIN INDER RAJ S | | |
| 发明人 | SLAYTON, MICHAEL H. BARTHE, PETER G. MAKIN, INDER RAJ S. | | |
| IPC分类号 | A61N7/02 A61B8/14 A61N7/00 A61B8/00 A61B8/08 G01S15/89 A61B90/00 | | |
| CPC分类号 | A61N7/02 A61B8/14 A61B8/429 A61B8/4483 A61B8/461 A61B8/483 G01S15/8906 G01S15/8936 H05K999/99 A61N7/00 A61N2007/0008 A61B8/4455 A61B2090/378 | | |
| 优先权 | 15/650246 2017-11-28 US 15/374918 2017-07-18 US 15/041829 2016-12-20 US 14/550720 2016-06-15 US 14/164598 2014-12-23 US 60/616753 2004-10-06 US | | |
| 其他公开文献 | US20180272159A1 | | |
| 外部链接 | Espacenet | | |

摘要(译)

一种用于向组织提供超声治疗的方法和系统，所述组织包含真皮的下部和进入真皮的脂肪小叶的近端突起。一个实施例将超声能量传递到该区域，产生热损伤并凝结脂肪小叶的近端突起，从而消除进入真皮的脂肪突起。一个实施例还可以包括在治疗之前，之后或期间使用相同或单独的探针的超声成像配置。此外，可以使用各种治疗水平的超声来增加脂肪代谢的速度。另外，超声的机械作用物理地破坏脂肪细胞团并拉伸纤维状结合。机械作用还会增强淋巴引流，刺激脂肪腐烂产物的排出。

